Teleflex (TFX) 10-Q 30 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 29, 2014	Jul. 21, 2014
Document And Entity Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	29-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'TFX	'
Entity Registrant Name	'TELEFLEX INC	'
Entity Central Index Key	'0000096943	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,396,149

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Net revenues	$468,105	$420,059	$906,651	$831,936
Cost of goods sold	224,017	210,569	441,404	421,926
Gross profit	244,088	209,490	465,247	410,010
Selling, general and administrative expenses	146,843	116,253	287,140	243,203
Research and development expenses	14,870	16,524	28,932	31,531
Restructuring and other impairment charges	7,623	12,962	15,403	22,121
Income from continuing operations before interest and taxes	74,752	63,751	133,772	113,155
Interest expense	16,062	14,425	31,466	28,618
Interest income	-146	-157	-333	-314
Income from continuing operations before taxes	58,836	49,483	102,639	84,851
Taxes on income from continuing operations	10,006	6,082	18,540	13,749
Income from continuing operations	48,830	43,401	84,099	71,102
Operating loss from discontinued operations	-1,594	-1,026	-1,619	-1,784
Tax benefit on loss from discontinued operations	-469	-260	-369	-556
Loss from discontinued operations	-1,125	-766	-1,250	-1,228
Net income	47,705	42,635	82,849	69,874
Less: Income from continuing operations attributable to noncontrolling interest	453	194	639	395
Net income attributable to common shareholders	47,252	42,441	82,210	69,479
Basic:	'	'	'	'
Income from continuing operations	$1.17	$1.05	$2.02	$1.72
Loss from discontinued operations	($0.03)	($0.02)	($0.03)	($0.03)
Net income	$1.14	$1.03	$1.99	$1.69
Diluted:	'	'	'	'
Income from continuing operations	$1.04	$0.99	$1.81	$1.64
Loss from discontinued operations	($0.02)	($0.01)	($0.03)	($0.03)
Net income	$1.02	$0.98	$1.78	$1.61
Dividends per share	$0.34	$0.34	$0.68	$0.68
Weighted average common shares outstanding	'	'	'	'
Basic	41,380	41,115	41,321	41,064
Diluted	46,392	43,429	46,071	43,238
Amounts attributable to common shareholders:	'	'	'	'
Income from continuing operations, net of tax	48,377	43,207	83,460	70,707
Loss from discontinued operations, net of tax	-1,125	-766	-1,250	-1,228
Net income	$47,252	$42,441	$82,210	$69,479

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Net income	$47,705	$42,635	$82,849	$69,874
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation, net of tax of $(531) and $4,461, $(3,719) and $(1,353) for the three and six month periods, respectively	1,173	-6,100	5,290	-32,805
Pension and other postretirement benefit plans adjustment, net of tax of $206, $519, $709 and $1,023 for the three and six month periods, respectively	618	866	1,242	1,956
Derivatives qualifying as hedges, net of tax of $40, $(111), $82, and $(7) for the three and six month periods, respectively	73	-192	143	-12
Other comprehensive income (loss), net of tax:	1,864	-5,426	6,675	-30,861
Comprehensive income	49,569	37,209	89,524	39,013
Less: comprehensive income attributable to non-controlling interest	455	2	707	244
Comprehensive income attributable to common shareholders	$49,114	$37,207	$88,817	$38,769

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Foreign currency translation, tax	($531)	$4,461	($3,719)	($1,353)
Pension and other postretirement benefits plans adjustment, tax	206	519	709	1,023
Derivatives qualifying as hedges, tax	$40	($111)	$82	($7)

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 29, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$237,382	$431,984
Accounts receivable, net	301,720	295,290
Inventories, net	356,467	333,621
Prepaid expenses and other current assets	38,386	39,810
Prepaid taxes	47,641	36,504
Deferred tax assets	50,497	52,917
Assets held for sale	9,161	10,428
Total current assets	1,041,254	1,200,554
Property, plant and equipment, net	343,408	325,900
Goodwill	1,373,356	1,354,203
Intangible assets, net	1,233,905	1,255,597
Investments in affiliates	1,465	1,715
Deferred tax assets	944	943
Other assets	69,501	70,095
Total assets	4,063,833	4,209,007
Current liabilities	'	'
Current borrowings	362,273	356,287
Accounts payable	73,533	71,967
Accrued expenses	80,040	74,868
Current portion of contingent consideration	2,959	4,131
Payroll and benefit-related liabilities	66,569	73,090
Accrued interest	9,991	8,725
Income taxes payable	21,817	23,821
Other current liabilities	35,308	22,231
Total current liabilities	652,490	635,120
Long-term borrowings	700,000	930,000
Deferred tax liabilities	517,433	514,715
Pension and postretirement benefit liabilities	102,194	109,498
Noncurrent liability for uncertain tax provisions	56,687	55,152
Other liabilities	50,650	48,506
Total liabilities	2,079,454	2,292,991
Commitments and contingencies	'	'
Total common shareholders' equity	1,982,277	1,913,527
Noncontrolling interest	2,102	2,489
Total equity	1,984,379	1,916,016
Total liabilities and equity	$4,063,833	$4,209,007

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013
Cash Flows from Operating Activities of Continuing Operations	'	'
Net income	$82,849	$69,874
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Loss from discontinued operations	1,250	1,228
Depreciation expense	23,997	19,876
Amortization expense of intangible assets	32,102	24,551
Amortization expense of deferred financing costs and debt discount	7,716	7,533
Changes in contingent consideration	-6,617	-7,926
Stock-based compensation	5,726	5,766
Deferred income taxes, net	2,811	-3,351
Other	-2,142	-8,243
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:	'	'
Accounts receivable	640	-18,084
Inventories	-16,385	-29,354
Prepaid expenses and other current assets	2,407	303
Accounts payable and accrued expenses	-1,731	1,163
Income taxes receivable and payable, net	-12,462	-7,093
Net cash provided by operating activities from continuing operations	120,161	56,243
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-30,850	-36,897
Proceeds from sale of assets and investments	4,139	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-36,954
Investment in affiliates	-60	-50
Net cash used in investing activities from continuing operations	-55,306	-73,901
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	'
Repayment of long-term borrowings	-480,000	'
Debt issuance fees	-3,275	'
Proceeds from share based compensation plans and the related tax impacts	2,391	3,892
Payments to noncontrolling interest shareholders	-1,094	-736
Payments for contingent consideration	'	-9,487
Dividends	-28,093	-27,944
Net cash used in financing activities from continuing operations	-260,071	-34,275
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,531	-1,437
Net cash used in discontinued operations	-1,531	-1,437
Effect of exchange rate changes on cash and cash equivalents	2,145	-2,251
Net decrease in cash and cash equivalents	-194,602	-55,621
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	$237,382	$281,418

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interest
In Thousands, except Share data
Beginning Balance at Dec. 31, 2012	$1,781,537	$43,102	$394,384	$1,601,460	($132,048)	($127,948)	$2,587
Beginning Balance (in shares) at Dec. 31, 2012	'	43,102,000	'	'	'	2,130,000	'
Net income	69,874	'	'	69,479	'	'	395
Cash dividends ($0.68 per share)	-27,944	'	'	-27,944	'	'	'
Other comprehensive income (loss)	-30,861	'	'	'	-30,710	'	-151
Distributions to noncontrolling interest shareholders	-736	'	'	'	'	'	-736
Shares issued under compensation plans	9,611	97	7,007	'	'	2,507	'
Shares issued under compensation plans, shares	'	97,000	'	'	'	-51,000	'
Deferred compensation	46	'	-9	'	'	55	'
Deferred compensation, shares	'	'	'	'	'	-1,000	'
Ending Balance at Jun. 30, 2013	1,801,527	43,199	401,382	1,642,995	-162,758	-125,386	2,095
Ending Balance (in shares) at Jun. 30, 2013	'	43,199,000	'	'	'	2,078,000	'
Beginning Balance at Dec. 31, 2013	1,916,016	43,243	409,338	1,696,424	-110,855	-124,623	2,489
Beginning Balance (in shares) at Dec. 31, 2013	'	43,243,000	'	'	'	2,064,000	'
Net income	82,849	'	'	82,210	'	'	639
Cash dividends ($0.68 per share)	-28,093	'	'	-28,093	'	'	'
Other comprehensive income (loss)	6,675	'	'	'	6,607	'	68
Distributions to noncontrolling interest shareholders	-1,094	'	'	'	'	'	-1,094
Shares issued under compensation plans	7,945	144	5,237	'	'	2,564	'
Shares issued under compensation plans, shares	'	144,000	'	'	'	-70,000	'
Deferred compensation	81	'	'	'	'	81	'
Deferred compensation, shares	'	'	'	'	'	-2,000	'
Ending Balance at Jun. 29, 2014	$1,984,379	$43,387	$414,575	$1,750,541	($104,248)	($121,978)	$2,102
Ending Balance (in shares) at Jun. 29, 2014	'	43,387,000	'	'	'	1,992,000	'

CONDENSED_CONSOLIDATED_STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Dividends per share	$0.34	$0.34	$0.68	$0.68

Basis_of_Presentation

Basis of Presentation	6 Months Ended
	Jun. 29, 2014
Basis of Presentation	'
	Note 1 — Basis of presentation
	We prepared the accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated on the same basis as our annual consolidated financial statements.
	In the opinion of management, our financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in our annual consolidated financial statements. The year-end condensed balance sheet data was derived from audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, our quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013.
	Effective January 1, 2014, the Company realigned its operating segments to reflect changes in the Company’s internal financial reporting structure. See Note 14 for additional information on the Company’s changed reporting structure.
	The Company’s share based compensation plan permits employees to elect to have shares withheld by the Company to satisfy their minimum statutory tax withholding obligations arising from the exercise or vesting of share based awards.  The Company then remits, in cash, the withholding taxes to the appropriate tax authorities on behalf of the employee.  For the six months ended June 29, 2014, the Company has classified such payments as a cash outflow from financing activities under the caption “Proceeds from share based compensation plans and the related tax impacts” within the condensed consolidated statement of cash flows.  The Company views the activity as, in effect, a repurchase of the employee’s shares.  The Company’s payments were previously reported as a cash outflow from operating activities; therefore, the Company reclassified the cash outflow for the six months ended June 30, 2013 of $2.3 million to conform to the presentation for the six months ended June 29, 2014 within the condensed consolidated statement of cash flows as well as the condensed consolidating statement of cash flows included in Note 15. The Company’s future filings incorporating financial periods prior to 2014 will also reflect this reclassification.
	Additionally, the Company made certain revisions to the prior year condensed consolidating statements of cash flows included in the condensed consolidated guarantor financial information included in Note 15 to correct errors identified in the fourth quarter 2013.
	As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

New_Accounting_Standards

New Accounting Standards	6 Months Ended
	Jun. 29, 2014
New Accounting Standards	'
	Note 2 — New accounting standards
	In April 2014, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of discontinued operations. Under the new guidance, only those disposals of components of an entity that represent a strategic shift that has or will have a major effect on an entity's operations and financial results will be reported as discontinued operations in an entity's financial statements. In addition, the new guidance requires additional disclosures for discontinued operations designed to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. The new guidance also requires disclosures regarding disposals of a significant component of an entity that does not qualify for discontinued operations reporting.This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014 with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the Company’s results of operations, cash flows or financial position.
	In May 2014, the FASB, in a joint effort with the International Accounting Standards Board, issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years.  Early application is not permitted. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows, and financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 29, 2014
Acquisitions	'
	Note 3 — Acquisitions
	On February 3, 2014, the Company acquired Mayo Healthcare Pty Limited, (“Mayo Healthcare”), a distributor of medical devices and supplies primarily in the Australian market. The total fair value of consideration for the Mayo Healthcare acquisition was $28.5 million, which included an initial payment of $29.0 million in cash, partially offset by a $0.5 million favorable working capital adjustment. Transaction expenses associated with the acquisition, which are included in selling, general and administrative expenses on the condensed consolidated statements of income were $0.3 million for the six months ended June 29, 2014. The results of operations of the Mayo Healthcare business are included in the condensed consolidated statements of income from the acquisition date. For the three months ended June 29, 2014, the Company recorded revenue and income from continuing operations before taxes related to the Mayo Healthcare business of $9.4 million and $3.2 million, respectively.  For the six months ended June 29, 2014, the Company recorded revenue and income from continuing operations before taxes related to the Mayo Healthcare business of $13.5 million and $3.8 million, respectively. Pro forma information is not presented as the Mayo Healthcare operations are not significant to the overall operations of the Company.
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo Healthcare acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	10,393
	Property, plant and equipment		306
	Customer lists intangible asset		9,335
	Goodwill		15,986
	Total assets acquired		36,020
	Liabilities
	Current liabilities		4,685
	Deferred tax liabilities		2,800
	Liabilities assumed		7,485
	Net assets acquired	$	28,535
	The Company is continuing to evaluate the Mayo Healthcare acquisition. Further adjustments to the fair value determination may be necessary as a result of the Company’s assessment of additional information related to the fair values of assets acquired and liabilities assumed, primarily with respect to deferred tax assets and liabilities and goodwill.
	Among the acquired assets, customer lists have a useful life of 10 years. The goodwill resulting from the acquisition primarily reflects the synergies expected to be realized from integration of the acquired business. Goodwill and the step-up in basis of the intangible assets in connection with stock acquisitions such as the Mayo Healthcare acquisition are not deductible for tax purposes.
	The Company made the following acquisitions during 2013, all of which were accounted for as business combinations:
	·	On December 2, 2013, the Company acquired Vidacare Corporation, (“Vidacare”), a provider of intraosseous, or inside the bone, access devices. This acquisition complements the Company’s vascular access and specialty product portfolios.
	·	On June 11, 2013, the Company acquired the assets of Ultimate Medical Pty. Ltd. and its affiliates (“Ultimate”), a supplier of airway management devices and related products. This acquisition complements the Company’s anesthesia product portfolio.
	·	On June 6, 2013, the Company acquired Eon Surgical, Ltd. (“Eon”), a developer of a minimally invasive microlaparoscopy surgical platform technology designed to enhance a surgeon’s ability to perform scarless surgery while producing better patient outcomes. This technology complements the Company’s surgical product portfolio.
	The total fair value of consideration for the 2013 acquisitions is estimated at $307.0 million. The results of operations of the acquired businesses and assets are included in the consolidated statements of income from their respective acquisition dates. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring_and_Other_Impair

Restructuring and Other Impairment Charges	6 Months Ended
	Jun. 29, 2014
Restructuring and Other Impairment Charges	'
	Note 4 — Restructuring and other impairment charges
	2014 Manufacturing Footprint Realignment
	On April 28, 2014, the Board of Directors approved a restructuring plan (the “2014 Manufacturing Footprint Realignment Plan”) involving the consolidation of operations and a related reduction in workforce at certain of the Company’s facilities, and will include the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the second quarter ended June 29, 2014 and are expected to be substantially completed by the end of 2017.
	The Company estimates that it will incur aggregate pre-tax charges in connection with these restructuring activities of approximately $42 to $53 million, most of which are expected to be incurred prior to the end of 2016. In addition, the Company estimates that $32 million to $40 million of the aggregate pre-tax charges will result in future cash outlays, most of which are expected to be incurred prior to the end of 2016.
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the 2014 Manufacturing Footprint Realignment Plan:
		Total estimated amount expected to be incurred
	Type of cost
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.
	The Company recorded expenses of $9.5 million for the three and six month ended June 29, 2014 related to the 2014 Manufacturing Footprint Realignment Plan. Of this amount, $8.6 million related to termination benefits and was recorded as restructuring expense and $0.9 million related to accelerated depreciation and other costs and was recorded as cost of sales. As of June 29, 2014, the Company has a restructuring reserve of $8.6 million in connection with the 2014 Manufacturing Footprint Realignment Plan all of which relates to termination benefits.
	As the program progresses, management will reevaluate the estimated costs set forth above, and may revise its estimates and the accounting charges relating to these actions, as appropriate, consistent with generally accepted accounting principles.
	2014 European Restructuring Plan
	On February 27, 2014, the Company committed to a restructuring plan (the “2014 European Restructuring Plan”), which impacts certain administrative functions in Europe and involves the consolidation of operations and a related reduction in workforce at certain of the Company’s European facilities.
	The Company estimates that it will record pre-tax charges of approximately $8 million to $9 million in connection with implementing the 2014 European Restructuring Plan. The Company anticipates that substantially all of these charges will involve employee termination benefits that will result in future cash outlays. For the three months ended June 29, 2014 the Company reversed $0.6 million of expense after determining certain termination benefit reserves would not be utilized. For the six months ended June 29, 2014, the Company incurred $8.1 million of charges primarily related to termination benefits. As of June 29, 2014, the Company had a reserve of $5.3 million in connection with this project.  The Company expects to complete this program in 2014.
	2014 Restructuring Charges
	In June 2014, the Company initiated programs to consolidate locations in Australia and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company estimates that it will incur an aggregate of $2 million to $3 million in restructuring and other impairment charges over the term of these restructuring programs, of which $1.8 million was incurred through June 29, 2014. These programs include costs related to termination benefits, contract termination costs and other exit costs. As of June 29, 2014, the Company has a reserve of $0.4 million in connection with these programs. The Company expects to complete the programs in 2014.
	LMA Restructuring Program
	In connection with the acquisition of substantially all of the assets of LMA International N.V. (the “LMA business”) in 2012, the Company formulated a plan related to the integration of the LMA business and the Company’s other businesses. The integration plan focuses on the closure of the LMA business’ corporate functions and the consolidation of manufacturing, sales, marketing, and distribution functions in North America, Europe and Asia.
	A reconciliation of the changes in accrued liabilities associated with the LMA restructuring program from December 31, 2013 through June 29, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals (reversals)		(29	)		(112	)		(3,231	)		—		(3,372	)
	Cash payments		(494	)		(317	)		(70	)		—		(881	)
	Foreign currency translation		—			2			(1	)		1		2
	Balance at June 29, 2014	$	29		$	-		$	384		$	17	$	430
	During the six months ended June 29, 2014, the Company reversed approximately $3.2 million in contract termination costs related to the settlement of a terminated distributor agreement.
	The Company does not expect to incur additional costs associated with this program. The Company expects to complete the program in 2015.
	2013 Restructuring Charges
	In 2013, the Company initiated programs to consolidate manufacturing facilities in North America and warehouse facilities in Europe and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company estimates that it will incur an aggregate of up to $11.0 million in restructuring and other impairment charges over the term of these restructuring programs, of which $10.8 million was incurred through June 29, 2014. These programs entail costs related to termination benefits, contract termination costs and charges related to post-closing obligations associated with its acquired businesses. As of June 29, 2014, the Company has a reserve of $1.6 million in connection with these programs. The Company expects to complete the programs in 2015.
	2012 Restructuring Charges
	In 2012, the Company identified opportunities to improve its supply chain strategy by consolidating its three North American warehouses into one centralized warehouse; and lower costs and improve operating efficiencies through the termination of certain distributor agreements in Europe, the closure of certain North American facilities and workforce reductions. Aside from nominal facility closure costs anticipated in 2014, the Company does not expect to incur additional costs associated with this program. As of June 29, 2014, the Company has a reserve of $0.6 million in connection with these projects. The Company expects to complete this program in 2015.
	Impairment Charges
	In the first quarter 2013, the Company recorded a $4.5 million in-process research and development (IPR&D) charge pertaining to a research and development project associated with the acquisition of the assets of Axiom Technology Partners LLP because technological feasibility had not yet been achieved and the Company determined that the subject technology had no future alternative use.
	There were no impairment charges recorded for the three and six months ended June 29, 2014 or for the three months ended June 30, 2013.
	The restructuring and other impairment charges recognized for the three and six months ended June 29, 2014 and June 30, 2013 consisted of the following:
	Three Months Ended June 29, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	2014 Manufacturing footprint realignment	$	8,577		$	—		$	—		$	—	$	8,577
	2014 European restructuring plan		(566	)		—			305			49		(212	)
	2014 Restructuring charges		476			—			1,174			131		1,781
	LMA restructuring program		(29	)		(154	)		(2,759	)		—		(2,942	)
	2013 Restructuring charges		317			—			57			22		396
	2012 Restructuring charges		(9	)		34			—			—		25
	2011 Restructuring plan		—			(2	)		—			—		(2	)
	Total restructuring and other impairment charges	$	8,766		$	(122	)	$	(1,223	)	$	202	$	7,623
	Three Months Ended June 30, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	802		$	293		$	2,839		$	7	$	3,941
	2013 Restructuring charges		1,131			—			3,391			2,828		7,350
	2012 Restructuring charges		1,216			102			293			5		1,616
	2011 Restructuring plan		—			—			—			—		—
	2007 Arrow integration program		—			55			—			—		55
	Total restructuring and other impairment charges	$	3,149		$	450		$	6,523		$	2,840	$	12,962
Six Months Ended June 29, 2014
(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
				Closure
				Costs
2014 Manufacturing footprint realignment	$	8,577		$	—		$	—		$	—	$	8,577
2014 European restructuring plan		7,752			—			305			49		8,106
2014 Restructuring charges		476			—			1,174			131		1,781
LMA restructuring program		(29	)		(112	)		(3,231	)		—		(3,372	)
2013 Restructuring charges		485			—			57			22		564
2012 Restructuring charges		(619	)		354			—			—		(265	)
2011 Restructuring plan		—			12			—			—		12
Total restructuring and other impairment charges	$	16,642		$	254		$	(1,695	)	$	202	$	15,403
Six Months Ended June 30, 2013
(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
				Closure
				Costs
LMA restructuring program	$	2,826		$	374		$	3,281		$	115	$	6,596
2013 Restructuring charges		1,552			—			3,391			2,887		7,830
2012 Restructuring charges		2,666			102			293			5		3,066
2007 Arrow integration program		—			135			—			—		135
		7,044			611			6,965			3,007		17,627
Impairment charges		—			—			—			4,494		4,494
Total restructuring and other impairment charges	$	7,044		$	611		$	6,965		$	7,501	$	22,121
Termination benefits include employee severance and retention for terminated employees.
Facility closure costs include general operating costs incurred subsequent to production shut-down as well as equipment relocation and other associated costs.
Contract termination costs include costs associated with terminating existing leases and distributor agreements.
Other costs include legal, outplacement and employee relocation costs and other employee-related costs.
Restructuring and other impairment charges by reportable segment for the three and six months ended June 29, 2014 and June 30, 2013 are set forth in the following table:
	Three Months Ended						Six Months Ended
	29-Jun-14			30-Jun-13			29-Jun-14			30-Jun-13
	(Dollars in thousands)						(Dollars in thousands)
Restructuring and other impairment charges
Vascular North America	$	5,887		$	130		$	5,962		$	627
Anesthesia/Respiratory North America		1,151			762			1,178			2,669
Surgical North America		—			2,800			—			7,294
EMEA		(1,575	)		7,913			6,315			9,207
Asia		519			147			597			245
OEM		—			588			—			588
All other		1,641			622			1,351			1,491
Total restructuring and other impairment charges	$	7,623		$	12,962		$	15,403		$	22,121

Inventories_Net

Inventories, Net	6 Months Ended
	Jun. 29, 2014
Inventories, Net	'
	Note 5 — Inventories, net
	Inventories as of June 29, 2014 and December 31, 2013 consisted of the following:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Raw materials	$	74,790		$	70,209
	Work-in-process		59,412			53,672
	Finished goods		255,244			242,113
			389,446			365,994
	Less: Inventory reserve		(32,979	)		(32,373	)
	Inventories, net	$	356,467		$	333,621

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets, Net	6 Months Ended
	Jun. 29, 2014
Goodwill and Other Intangible Assets, Net	'
	Note 6 — Goodwill and other intangible assets, net
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the six months ended June 29, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia		All			Total
		North America			Respiratory			North America								Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946	$	284,223		$	1,686,331
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
			254,517			60,122			250,506			373,417			136,946		278,695			1,354,203
	Goodwill related to		—			—			—			—			15,986		—			15,986
	acquisitions
	Translation adjustment		—			(82	)		—			(279	)		3,636		(108	)		3,167
	Balance as of June 29, 2014
	Goodwill		474,044			167,113			250,506			373,138			156,568		284,115			1,705,484
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
		$	254,517		$	60,040		$	250,506		$	373,138		$	156,568	$	278,587		$	1,373,356
	The following table provides information as of June 29, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		June 29,			December 31,			June 29,			December 31,
		2014			2013			2014			2013
		(Dollars in thousands)
	Customer relationships	$	638,315		$	628,020		$	(183,363	)	$	(168,223	)
	In-process research and development		68,786			68,786			—			—
	Intellectual property		435,811			435,869			(133,795	)		(118,086	)
	Distribution rights		16,761			16,797			(14,726	)		(14,592	)
	Trade names		408,050			407,879			(2,089	)		(1,148	)
	Noncompete agreements		337			337			(182	)		(42	)
		$	1,568,060		$	1,557,688		$	(334,155	)	$	(302,091	)
	During the first quarter 2013, the Company recorded an IPR&D charge of $4.5 million. See Note 4 for additional information.
	In May 2012, the Company acquired Semprus BioSciences, a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications.  The Company experienced unexpected difficulties with respect to the development of the Semprus technology, which the Company is currently attempting to resolve through further research and testing. Failure to resolve these issues may result in a reduction of the expected future cash flows related to the Semprus technology and could result in the recognition of impairment charges with respect to the related assets, which could be material.  As of June 29, 2014, the Company has recorded assets at risk of approximately $41.0 million related to this investment.
	Amortization expense related to intangible assets was $16.1 million and $12.1 million for the three months ended June 29, 2014 and June 30, 2013, respectively, and $32.1 million and $24.6 million for the six months ended June 29, 2014 and June 30, 2013, respectively.  Estimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014		$	33,000
	2015			55,500
	2016			54,500
	2017			54,000
	2018			53,500
	2019			51,000

Borrowings

Borrowings	6 Months Ended
	Jun. 29, 2014
Borrowings	'
	Note 7 — Borrowings
	The components of long-term debt at June 29, 2014 and December 31, 2013 are as follows:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 2.15% at June 29,	$	200,000		$	680,000
	2014, due 7/16/2018
	3.875% Convertible Senior Subordinated Notes		400,000			400,000
	6.875% Senior Subordinated Notes due 2019		250,000			250,000
	5.25% Senior Notes due 2024		250,000			-
	Total borrowings		1,100,000			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible		(42,427	)		(48,413	)
	Senior Subordinated Notes
			1,057,573			1,281,587
	Current portion of borrowings		(357,573	)		(351,587	)
		$	700,000		$	930,000
	5.25% Senior Notes
	On May 21, 2014, the Company issued $250.0 million of 5.25% Senior Notes due 2024 (the “2024 Notes”). The Company will pay interest on the 2024 Notes semi-annually on June 15 and December 15, commencing on December 15, 2014, at a rate of 5.25% per year. The 2024 Notes will mature on June 15, 2024, unless earlier redeemed or purchased by the Company at the holder’s option under specified circumstances following a Change of Control or Asset Sale (each as defined in the Indenture related to the 2024 Notes) or upon the Company’s election to exercise its optional redemption rights, as described below. The Company incurred transaction fees of approximately $4.7 million, including underwriters’ discounts and commissions in connection with the offering of the 2024 Notes, which were recorded as a deferred asset and are being amortized over the term of the 2024 Notes. The Company used $245.0 million of the proceeds to repay borrowings under its revolving credit facility.
	The Company's obligations under the 2024 Notes are fully and unconditionally guaranteed, jointly and severally, by each of the Company’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under the Company’s revolving credit facility and by certain of the Company’s other wholly-owned domestic subsidiaries.
	At any time on or after June 15, 2019, the Company may, on one or more occasions, redeem some or all of the 2024 Notes at a redemption price of 102.625% of the principal amount of the 2024 Notes subject to redemption, declining, in annual increments of 0.875%, to 100% of the principal amount on June 15, 2022, plus accrued and unpaid interest.  In addition, at any time prior to June 15, 2019, the Company may, on one or more occasions, redeem some or all of the 2024 Notes at a redemption price equal to 100% of the principal amount of the 2024 Notes redeemed, plus a “make-whole” premium and any accrued and unpaid interest.  The “make-whole” premium is the greater of (a) 1.0% of the principal amount of the 2024 Notes subject to redemption or (b) the excess, if any, over the principal amount of the 2024 Notes of the present value, on the redemption date of the sum of (i) the June 15, 2019 optional redemption price plus (ii) all required interest payments on the 2024 Notes through June 15, 2019 (other than accrued and unpaid interest to the redemption date), calculated based on a specified Treasury rate, generally for the period most nearly equal to the period from the redemption date to June 15, 2019, plus 50 basis points.
	In addition, at any time prior to June 15, 2017, the Company may, on one or more occasions, redeem up to 35% of the aggregate principal amount of the 2024 Notes, using the proceeds of specified types of Company equity offerings and subject to specified conditions, at a redemption price equal to 105.25% of the principal amount of the Notes redeemed, plus accrued and unpaid interest.
	The 2024 Notes contain covenants that, among other things, limit or restrict the Company’s ability, and the ability of its subsidiaries, to incur debt, create liens, consolidate, merge or dispose of certain assets, make certain investments, engage in acquisitions, pay dividends on, repurchase or make distributions in respect of capital stock and enter into swap agreements.
	Classification of 3.875% Convertible Notes as a Current Liability
	The Company’s 3.875% Convertible Senior Subordinated Notes due 2017 (the “Convertible Notes”) are convertible under certain circumstances, including in any fiscal quarter following an immediately preceding fiscal quarter in which the last reported sales price per share of our common stock for at least 20 days during a period of 30 consecutive trading days ending on the last day of such fiscal quarter exceeds 130% of the $61.32 per share conversion price of the Convertible Notes (approximately $79.72). Since the fourth quarter of 2013, the Company’s closing stock price has exceeded the 130% threshold described above and, accordingly, the Convertible Notes have been classified as a current liability as of June 29, 2014 and December 31, 2013. The determination of whether or not the Convertible Notes are convertible under such circumstances is made each quarter until maturity or conversion. Consequently, the Convertible Notes may not be convertible in one or more future quarters if the common stock price-based contingent conversion threshold is not met in such quarters, in which case the Convertible Notes would again be classified as long-term debt unless another conversion event set forth in the Convertible Notes has occurred. The Company has elected a net settlement method to satisfy the conversion obligation, under which it may settle the principal amount of the Convertible Notes in cash and settle the excess of the conversion value of the Convertible Notes over the principal amount of the notes in shares; however, cash will be paid in lieu of fractional shares. While the Company believes it has sufficient liquidity to repay the principal amounts due through a combination of its existing cash on hand and borrowings under its credit facility, the Company’s use of these funds could adversely affect our results of operations and liquidity. The classification of the Convertible Notes as a current liability had no impact on our financial covenants.
	Fair Value of Long-Term Debt
	The carrying amount of long-term debt reported in the consolidated balance sheet as of June 29, 2014 is $1,057.6 million. The Company uses quoted market prices to estimate the fair value of its publicly traded debt. To estimate the fair value of debt for which there are no quoted market prices, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of June 29, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	968,108
	Level 2		457,051
	Total	$	1,425,159

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 29, 2014
Financial Instruments	'
	Note 8 — Financial instruments
	The Company uses derivative instruments for risk management purposes. Forward exchange contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive income and thereafter is recognized in the condensed consolidated statement of income in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in the condensed consolidated statement of earnings in the period in which such gains and losses occur.
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of June 29, 2014 and December 31, 2013:
		June 29,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign exchange contracts:
	Prepaid expenses and other current assets	$	902		$	—
	Total asset derivatives	$	902		$	—
	Liability derivatives:
	Foreign exchange contracts:
	Other current liabilities	$	621		$	—
	Total liability derivatives	$	621		$	—
	The total notional amount for all open foreign exchange contracts as of June 29, 2014 is approximately $42.6 million. As of December 31, 2013, the Company had no open forward rate exchange contracts.
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three and six months ended June 29, 2014 and June 30, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		Three Months Ended						Six Months Ended
		June 29,			June 30,			June 29,		June 30,
		2014			2013			2014		2013
		(Dollars in thousands)
	Foreign exchange contracts	$	73		$	(192	)	$	143	$	(12	)
	Total	$	73		$	(192	)	$	143	$	(12	)
	See Note 10 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) to expense (income), net of tax.
	There was no ineffectiveness related to the Company’s derivatives used during the three and six months ended June 29, 2014 and June 30, 2013.
	Based on exchange rates at June 29, 2014, approximately $0.1 million of unrealized gains, net of tax, within AOCI are expected to be reclassified from AOCI to the condensed consolidated statement of income during the remainder of 2014. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates.
	Concentration of Credit Risk
	Concentrations of credit risk with respect to trade accounts receivable is generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ economies.
	In the ordinary course of business, the Company grants non-interest bearing trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of its customers’ financial condition, (iii) monitors the payment history and aging of its customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.
	An allowance for doubtful accounts is maintained for accounts receivable based on the Company’s historical collection experience and expected collectability of the accounts receivable, considering the period an account is outstanding, the financial position of the customer and information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. Our allowance for doubtful accounts was $10.2 million and $10.7 million at June 29, 2014 and December 31, 2013, respectively.
	In light of the disruptions in global economic markets in recent years, the Company instituted enhanced measures, within countries where the Company has collectability concerns, to facilitate customer-by-customer risk assessment when estimating the allowance for doubtful accounts. Such measures include, among others, monthly credit control committee meetings, at which customer credit risks are identified after review of, among other things, accounts that exceed specified credit limits, payment delinquencies and other customer issues. In addition, for some of the Company’s non-government customers, the Company instituted measures designed to reduce its risk exposures, including issuing dunning letters, reducing credit limits, requiring that payments accompany orders and instituting legal action with respect to delinquent accounts. With respect to government customers, the Company evaluates receivables for potential collection risks associated with the availability of government funding and reimbursement practices.
	Some of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided. Collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal, resulted in an increase in the allowance for doubtful accounts related to these countries. If the financial condition of these customers or the healthcare systems in these countries deteriorate such that the ability of an increasing number of customers to make payments is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal as a percentage of the Company’s net current and long-term accounts receivable at June 29, 2014 and December 31, 2013 are as follows:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.9 million and $7.9 million at June 29, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal(1)	$	95,653		$	97,852
	Percentage of total net current and long-term accounts receivable		30.8	%		31	%
	-1	The long-term portion of accounts receivable, net at June 29, 2014 and December 31, 2013 was $12.7 million and $17.6 million, respectively.
	For the six months ended June 29, 2014 and June 30, 2013, net revenues from customers in Spain, Italy, Greece and Portugal were $79.6 million and $73.7 million, respectively.

Fair_Value_Measurement

Fair Value Measurement	6 Months Ended
	Jun. 29, 2014
Fair Value Measurement	'
	Note 9 — Fair value measurement
	For a description of the fair value hierarchy, see Note 10 to the Company’s 2013 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of June 29, 2014 and December 31, 2013:
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		June 29,				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,535			$	6,535	$	—	$	—
	Derivative assets		902				—		902		—
	Derivative liabilities		621				—		621		—
	Contingent consideration liabilities		13,696				—		—		13,696
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		December 31, 2013				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150			$	6,150	$	—	$	—
	Contingent consideration liabilities		20,313				—		—		20,313
	There were no transfers of financial assets or liabilities carried at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the six months ended June 29, 2014.
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the six months ended June 29, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations		(6,617	)
	Balance - June 29, 2014	$	13,696
	For the three and six months ended June 29, 2014, the Company recorded net reductions to contingent consideration liabilities of $4.4 million and $6.7 million, respectively, and for the three and six months ended June 30, 2013, the Company recorded reductions to contingent consideration liabilities of $6.6 million and $8.1 million, respectively.   These reductions were the result of changes in probabilities associated with certain regulatory and sales milestones.
	Valuation Techniques
	The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to pay benefits under certain deferred compensation plans and other compensatory arrangements. The investment assets of the trust are valued using quoted market prices.
	The Company’s financial assets and financial liabilities valued based upon Level 2 inputs are comprised of foreign currency forward exchange contracts. The Company uses forward rate exchange contracts to manage currency transaction exposure. The fair value of the foreign currency forward exchange contracts represents the amount required to enter into offsetting contracts with similar remaining maturities based on quoted market prices. The Company has taken into account the creditworthiness of the counterparties in measuring fair value.
	The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company accounts for contingent consideration in accordance with applicable accounting guidance related to business combinations. In connection with several of its acquisitions, the Company agreed to pay contingent consideration upon the achievement of specified objectives, including receipt of regulatory approvals, achievement of sales targets and, in some instances, the passage of time (collectively, “milestone payments”), and therefore recorded contingent consideration liabilities at the time of the acquisitions. The Company is required to reevaluate the fair value of contingent consideration each reporting period based on new developments and record changes in fair value until such consideration is satisfied through payment upon the achievement of the specified objectives or is no longer payable due to failure to achieve the specified objectives.
	It is estimated that milestone payments will occur in 2015 and may extend until 2018 or later. As of June 29, 2014, the range of undiscounted amounts the Company could be required to pay for contingent consideration arrangements is between zero and $56.5 million. The Company determines the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration liability associated with future milestone payments is based on several factors including:
	—	estimated cash flows projected from the success of market launches;
	—	the estimated time and resources needed to complete the development of acquired technologies;
	—	the uncertainty of obtaining regulatory approvals within the required time periods; and
	—	the risk adjusted discount rate for fair value measurement.
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of June 29, 2014:
			Valuation Technique		Unobservable Input		Range (Weighted Average)
	Contingent consideration		Discounted cash flow		Discount rate		1.6%—10% (8.6%)
					Probability of payment		0%—100% (32.0%)
	As of June 29, 2014, of the $13.7 million of total recorded liabilities for contingent consideration, the Company has recorded approximately $3.0 million in Current portion of contingent consideration and the remaining $10.7 million in Other liabilities.

Changes_in_Shareholders_Equity

Changes in Shareholders' Equity	6 Months Ended
	Jun. 29, 2014
Changes in Shareholders' Equity	'
	Note 10 — Changes in shareholders’ equity
	In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generated from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio (generally, the ratio of Consolidated Total Indebtedness to Consolidated EBITDA, as defined in the senior credit agreements) exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through June 29, 2014, no shares have been purchased under this Board authorization.
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended						Six Months Ended
		29-Jun-14			30-Jun-13			29-Jun-14			30-Jun-13
		(Shares in thousands)
	Basic		41,380			41,115			41,321			41,064
	Dilutive effect of share based awards		413			374			442			384
	Dilutive effect of 3.875% Convertible Notes and warrants		4,599			1,940			4,308			1,790
	Diluted		46,392			43,429			46,071			43,238
	Weighted average shares that were antidilutive and therefore not included in the calculation of earnings per share were approximately 6.4 million and 6.5 million for the three and six months ended June 29, 2014 respectively, and approximately 7.9 million for both the three and six month periods ended June 30, 2013, respectively.
	The Convertible Notes are included in the diluted net income per share calculation only during periods in which the average market price of our common stock was above the applicable conversion price of the Convertible Notes, or $61.32 per share, and, therefore, the impact of conversion would not be anti-dilutive. In these periods, under the treasury stock method, we calculate the number of shares issuable under the terms of the Convertible Notes based on the average market price of the stock during the period, and include that number in the total diluted shares outstanding for the period.
	In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge economically reduces the dilutive impact of the Convertible Notes. However, because applicable accounting guidance requires the Company to separately analyze the impact of the convertible note hedge agreements and the impact of the warrant agreements on diluted weighted average shares outstanding, the impact of the convertible note hedge agreements are excluded from the calculation of earnings per share because it would be anti-dilutive. The anti-dilutive shares associated with the convertible note hedges are 2.7 million and 2.6 million for the three and six months ended June 29, 2014, respectively and 1.5 million and 1.4 million for the three and six months ended June 30, 2013, respectively. The treasury stock method is applied when the warrants are in-the-money, assuming the proceeds from the exercise of the warrants are used to repurchase shares based on the average stock price during the period. The strike price of the warrants is approximately $74.65 per share of common stock. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 1.9 million and 1.7 million for the three and six months ended June 29, 2014, respectively and 0.4 million and 0.3 million for the three and six months ended June 30, 2013, respectively.
	For additional information regarding the convertible notes and convertible note hedge and warrant agreements see Note 8 to the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the six months ended June 29, 2014 and June 30, 2013:
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2013	$	—		$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss)		233			(256	)		5,222			5,199
	before reclassifications
	Amounts reclassified from		(90	)		1,498			—			1,408
	accumulated other
	comprehensive  income (loss)
	Net current-period other		143			1,242			5,222			6,607
	comprehensive income
	Balance at June 29, 2014	$	143		$	(95,795	)	$	(8,596	)	$	(104,248	)
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)	$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss)		362			(452	)		(32,654	)		(32,744	)
	before reclassifications
	Amounts reclassified from		(374	)		2,408			—			2,034
	accumulated other
	comprehensive income (loss)
	Net current-period other		(12	)		1,956			(32,654	)		(30,710	)
	comprehensive income (loss)
	Balance at June 30, 2013	$	(393	)	$	(125,301	)	$	(37,064	)	$	(162,758	)
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three and six months ended June 29, 2014 and June 30, 2013:
		Three Months Ended						Six Months Ended
		June 29,			June 30,			June 29,			June 30,
		2014			2013			2014			2013
		(Dollars in thousands)
	Gains and losses on foreign exchange contracts:
	Cost of goods sold	$	(52	)	$	(194	)	$	(129	)	$	(696	)
	Total before tax		(52	)		(194	)		(129	)		(696	)
	Tax expense		5			95			39			322
	Net of tax	$	(47	)	$	(99	)	$	(90	)	$	(374	)
	Amortization of pension and other postretirement
	benefit items:
	Actuarial losses/(gains) (1)	$	1,103		$	1,618		$	2,205		$	3,764
	Prior-service costs(1)		(6	)		(6	)		(11	)		(11	)
	Transition obligation(1)		—			1			-			2
	Total before tax		1,097			1,613			2,194			3,755
	Tax expense		(382	)		(660	)		(696	)		(1,347	)
	Net of tax	$	715		$	953		$	1,498		$	2,408
	Total reclassifications, net of tax	$	668		$	854		$	1,408		$	2,034
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_Income_from_Continuin

Taxes on Income from Continuing Operations	6 Months Ended
	Jun. 29, 2014
Taxes on Income from Continuing Operations	'
	Note 11 — Taxes on income from continuing operations
		Three Months Ended					Six Months Ended
		June 29,			June 30,		June 29,			June 30,
		2014			2013		2014			2013
	Effective income tax rate		17	%		12.30%		18.1	%		16.20%
	The effective income tax rate for the three and six months ended June 29, 2014 was 17.0% and 18.1%, respectively and 12.3% and 16.2% for the three and six months ended June 30, 2013, respectively. The effective tax rate for the three and six months ended June 29, 2014 benefited from a shift in the mix of taxable income to foreign jurisdictions that have lower statutory rates.  Nevertheless, the effective tax rate for the three and six months ended June 30, 2013 was lower, reflecting the realization of net tax benefits resulting from the resolution of a foreign tax matter and the expiration of statutes of limitation for a US state matter.

Pension_and_Other_Postretireme

Pension and Other Postretirement Benefits	6 Months Ended
	Jun. 29, 2014
Pension and Other Postretirement Benefits	'
	Note 12 — Pension and other postretirement benefits
	The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of June 29, 2014, the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, except certain postretirement benefit plans covering employees subject to a collective bargaining agreement, are frozen.
	The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds.
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits				Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended				Six Months Ended						Six Months Ended
		June 29,			June 30,			June 29,		June 30,		June 29,			June 30,			June 29,		June 30,
		2014			2013			2014		2013		2014			2013			2014		2013
		(Dollars in thousands)
	Service cost	$	447		$	464		$	138	$	161	$	897		$	929		$	276	$	325
	Interest cost	$	4,486			4,142		$	596		542		8,969			8,281			1,193		1,541
	Expected return on plan assets	$	(6,264	)		(5,774	)	$	—		—		(12,524	)		(11,544	)		—		—
	Net amortization and deferral	$	1,070			1,414		$	27		202		2,141			2,824			53		932
	Net benefit expense (income)	$	(261	)	$	246		$	761	$	905	$	(517	)	$	490		$	1,522	$	2,798
	The Company’s pension contributions are expected to be approximately $9.4 million during 2014, of which $2.3 million and $4.7 million were made during the three and six months ended June 29, 2014, respectively.

Commitments_and_Contingent_lia

Commitments and Contingent liabilities	6 Months Ended
	Jun. 29, 2014
Commitments and Contingent Liabilities	'
	Note 13 — Commitments and contingent liabilities
	Operating leases: The Company uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the terms of the applicable lease agreement. At June 29, 2014, the Company had no residual value guarantee obligations related to its operating leases.
	As of June 29, 2014, the Company recorded $24.8 million in property, plant and equipment representing the estimated fair value of the Company’s percentage of the costs to construct a building under a build-to-suit lease. The build-to-suit lease was entered into in August 2013 and amended in March of 2014 and relates to a U.S. operating facility. Construction on the build-to-suit facility commenced in September 2013 and is expected to be completed in October 2014. The estimated fair value of the Company’s percentage of the construction costs to complete the build-to-suit lease is approximately $28.3 million. For accounting purposes, the Company is deemed the owner of the asset during the construction period and is required to record the estimated fair value of the Company’s percentage of the construction costs as construction in progress during the construction period and a related liability in the same amount. These amounts do not reflect the Company’s cash obligations, but represent the landlord’s costs to construct the Company’s portion of the building and tenant improvements. Based on current expectations, the Company believes that there are no continuing involvement requirements that would prohibit the Company from derecognizing the assets and related liabilities upon commencement of the respective lease terms.
	Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.
	Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At June 29, 2014 and December 31, 2013, the Company has recorded $2.2 million and $2.5 million, respectively, in accrued liabilities and $5.4 million and $5.8 million, respectively, in other liabilities relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of June 29, 2014. The time frame, over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.
	Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. As of June 29, 2014 and December 31, 2013, the Company has recorded reserves of approximately $5.0 million and $6.8 million, respectively, in connection with such contingencies, representing what it believes to be a better estimate of the cost than any other amount within the range of estimated possible losses that will be incurred to resolve these matters.    Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that any such actions are likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected future developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to our business, financial condition, results of operations or liquidity.
	Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of July 29, 2014, the most significant tax examinations in process are in Austria, Canada, the Czech Republic, Germany and the United States. In conjunction with these examinations and as a regular and routine practice, the Company may establish reserves or adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.
	Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Business_Segment_Information

Business Segment Information	6 Months Ended
	Jun. 29, 2014
Business Segment Information	'
	Note 14 — Business segment information
	An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The Company does not evaluate its operating segments using discrete asset information.
	Effective January 1, 2014, the Company realigned its operating segments due to changes in the Company’s internal financial reporting structure. The Company’s North American Vascular, Anesthesia/Respiratory and Surgical businesses, which previously comprised much of the former Americas reportable segment, are now separate reportable segments.  As a result, the Company now has six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM. Certain operating segments are not material and are therefore included in the “All other” line item in tabular presentations of segment information. Additionally, the Company made changes to the allocation methodology of certain costs, including manufacturing variances and research and development costs, among the businesses to improve accountability, which resulted in changes to the previously reported segment profitability. All prior comparative periods have been restated to reflect these changes.
	The Company’s Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA and Asia reportable segments design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
	The following tables present the Company’s segment results for the three and six months ended June 29, 2014 and June 30, 2013:
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Revenue
	Vascular North America	$	64,187		$	56,746		$	126,694		$	113,420
	Anesthesia/Respiratory North America		55,049			58,516			109,763			116,690
	Surgical North America		37,969			37,749			73,200			74,437
	EMEA		154,670			137,842			304,914			280,260
	Asia		62,539			50,409			112,142			92,777
	OEM		36,610			32,110			69,791			63,448
	All other		57,081			46,687			110,147			90,904
	Consolidated net revenues	$	468,105		$	420,059		$	906,651		$	831,936
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	9,988		$	6,326		$	19,381		$	11,352
	Anesthesia/Respiratory North America		6,293			9,264			11,980			14,942
	Surgical North America		14,366			13,651			24,914			27,313
	EMEA		30,080			21,226			56,961			44,468
	Asia		17,096			13,971			29,932			26,067
	OEM		8,296			7,734			14,900			14,094
	All other		10,355			9,507			20,121			11,522
	Total segment operating profit (1)		96,474			81,679			178,189			149,758
	Unallocated expenses (2)		(21,722	)		(17,928	)		(44,417	)		(36,603	)
	Income from continuing operations before	$	74,752		$	63,751		$	133,772		$	113,155
	Interest and taxes
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	8,066		$	6,875		$	15,921		$	13,434
	Anesthesia/Respiratory North America		3,708			2,874			8,136			6,715
	Surgical North America		1,666			2,678			4,035			5,232
	EMEA		9,673			6,843			18,610			13,994
	Asia		2,305			1,203			4,143			2,415
	OEM		1,608			1,213			3,064			2,361
	All other		5,376			3,933			9,906			7,809
	Consolidated depreciation and amortization	$	32,402		$	25,619		$	63,815		$	51,960
	Geographic Data
	The following table provides total net revenues for the three and six months ended June 29, 2014 and June 30, 2013 and total net property, plant and equipment by geographic region as of June 29, 2014 and December 31, 2013:
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	228,349		$	210,833		$	444,810		$	418,347
	Other Americas		15,188			14,527			29,958			28,678
	Germany		35,264			32,708			69,254			66,459
	Other Europe		138,929			108,068			273,713			214,754
	All other		50,375			53,923			88,916			103,698
		$	468,105		$	420,059		$	906,651		$	831,936
		29-Jun-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	198,266		$	203,985
	Other Americas		12,160			12,350
Germany		12,129			12,135
Other Europe		80,075			61,891
All other		40,778			35,539
	$	343,408		$	325,900

Condensed_consolidated_guarant

Condensed consolidated guarantor financial information	6 Months Ended
	Jun. 29, 2014
Condensed consolidated guarantor financial information	'
	Note 15 —Condensed consolidated guarantor financial information
	In June 2011, Teleflex Incorporated (referred to below as “Parent Company”) issued $250 million of 6.875% senior subordinated notes through a registered public offering. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income (loss) for the three and six months ended June 29, 2014 and June 30, 2013, condensed consolidating balance sheets as of June 29, 2014 and December 31, 2013 and condensed consolidating statements of cash flows for the six months ended June 29, 2014 and June 30, 2013, provide consolidated information for:
	a.	Parent Company, the issuer of the guaranteed obligations;
	b.	Guarantor Subsidiaries, on a combined basis;
	c.	Non-guarantor subsidiaries, on a combined basis; and
	d.	Parent Company and its subsidiaries on a consolidated basis.
	The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidated financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation.
	Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.
	The Company adjusted the 2013 condensed consolidating statement of cash flows included within the guarantor financial information to correctly present dividends received from subsidiaries as an operating activity. The corrections had no impact on the consolidated financial information, but only resulted in reclassifications among the parent, guarantor subsidiaries, non-guarantor subsidiaries and eliminations. The Company does not consider the errors to be material to the previously issued consolidated financial statements.
	The following table illustrates the increase/(decrease) to the previously reported amounts for the six months ended June 30, 2013:
		Six Months Ended June 30, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing	$	1,200		$	46,389		$	3,738		$	(51,327	)	$	—
	Operations
	Cash Flows from Financing Activities of Continuing
	Operations:
	Intercompany transactions		(1,200	)		(28,989	)		30,189			—			—
	Intercompany dividends paid		—			(17,400	)		(33,927	)		51,327			—
	Cash Flows from Financing Activities of Continuing	$	(1,200	)	$	(46,389	)	$	(3,738	)	$	51,327		$	—
	Operations
	The Company will also revise the previously reported interim condensed consolidating statements of cash flows for the nine months ended September 29, 2013 when presented in future filings.
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended June 29, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	290,280		$	317,651		$	(139,826	)	$	468,105
	Cost of goods sold		-			176,028			177,009			(129,020	)		224,017
	Gross profit		-			114,252			140,642			(10,806	)		244,088
	Selling, general and administrative expenses		11,025			76,575			59,135			108			146,843
	Research and development expenses		-			12,885			1,985			-			14,870
	Restructuring and other impairment charges		-			8,679			(1,056	)		-			7,623
	Income (loss) from continuing operations		(11,025	)		16,113			80,578			(10,914	)		74,752
	before interest, and taxes
	Interest expense		35,155			(20,740	)		1,647			-			16,062
	Interest income		-			-			(146	)		-			(146	)
	Income (loss) from continuing operations		(46,180	)		36,853			79,077			(10,914	)		58,836
	before taxes
	Taxes (benefit) on income (loss) from continuing		(15,710	)		13,535			14,344			(2,163	)		10,006
	operations
	Equity in net income of consolidated subsidiaries		78,802			57,250			98			(136,150	)		-
	Income from continuing operations		48,332			80,568			64,831			(144,901	)		48,830
	Operating loss from discontinued operations		(1,594	)		-			-			-			(1,594	)
	Taxes (benefit) on income (loss) from		(514	)		-			45			-			(469	)
	discontinued operations
	Loss from discontinued operations		(1,080	)		-			(45	)		-			(1,125	)
	Net income		47,252			80,568			64,786			(144,901	)		47,705
	Less: Income from continuing operations		-			-			453			-			453
	attributable to noncontrolling interests
	Net income attributable to common		47,252			80,568			64,333			(144,901	)		47,252
	shareholders
	Other comprehensive income (loss) attributable		1,862			(2,607	)		(2,264	)		4,871			1,862
	to common shareholders
	Comprehensive income attributable	$	49,114		$	77,961		$	62,069		$	(140,030	)	$	49,114
	to common shareholders
		Three Months Ended June 30, 2013
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	248,012		$	239,147		$	(67,100	)	$	420,059
Cost of goods sold		-			143,732			136,322			(69,485	)		210,569
Gross profit		-			104,280			102,825			2,385			209,490
Selling, general and administrative expenses		14,899			59,336			42,418			(400	)		116,253
Research and development expenses		-			14,082			2,442			-			16,524
Restructuring and other impairment charges		-			1,511			11,451			-			12,962
Income (loss) from continuing operations before		(14,899	)		29,351			46,514			2,785			63,751
interest, and taxes
Interest expense		33,655			(21,017	)		1,787			-			14,425
Interest income		3			-			(160	)		-			(157	)
Income (loss) from continuing operations		(48,557	)		50,368			44,887			2,785			49,483
before taxes
Taxes (benefit) on income (loss) from continuing		(17,287	)		13,729			9,515			125			6,082
operations
Equity in net income of consolidated subsidiaries		74,433			31,599			-			(106,032	)		-
Income from continuing operations		43,163			68,238			35,372			(103,372	)		43,401
Operating loss from discontinued operations		(1,026	)		-			-			-			(1,026	)
Taxes (benefit) on income (loss) from		(304	)		-			44			-			(260	)
discontinued operations
Loss from discontinued operations		(722	)		-			(44	)		-			(766	)
Net income		42,441			68,238			35,328			(103,372	)		42,635
Less: Income from continuing operations		-			-			194			-			194
attributable to noncontrolling interests
Net income attributable to common		42,441			68,238			35,134			(103,372	)		42,441
shareholders
Other comprehensive income (loss) attributable		(5,234	)		(1,224	)		(3,559	)		4,783			(5,234	)
to common shareholders
Comprehensive income attributable	$	37,207		$	67,014		$	31,575		$	(98,589	)	$	37,207
to common shareholders
	Six Months Ended June 29, 2014
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net revenues	$	-		$	552,705		$	566,088		$	(212,142	)	$	906,651
Cost of goods sold		-			328,396			314,882			(201,874	)		441,404
Gross profit		-			224,309			251,206			(10,268	)		465,247
Selling, general and administrative expenses		21,803			157,970			107,056			311			287,140
Research and development expenses		-			24,895			4,037			-			28,932
Restructuring and other impairment charges		-			8,491			6,912			-			15,403
Income (loss) from continuing operations		(21,803	)		32,953			133,201			(10,579	)		133,772
before interest, and taxes
Interest expense		68,881			(40,647	)		3,232			-			31,466
Interest income		-			-			(333	)		-			(333	)
Income (loss) from continuing operations		(90,684	)		73,600			130,302			(10,579	)		102,639
before taxes
Taxes (benefit) on income (loss) from continuing		(31,130	)		30,753			23,176			(4,259	)		18,540
operations
Equity in net income of consolidated subsidiaries		142,926			100,358			192			(243,476	)		-
Income from continuing operations		83,372			143,205			107,318			(249,796	)		84,099
Operating loss from discontinued operations		(1,619	)		-			-			-			(1,619	)
Taxes (benefit) on income (loss) from		(457	)		-			88			-			(369	)
discontinued operations
Loss from discontinued operations		(1,162	)		-			(88	)		-			(1,250	)
Net income		82,210			143,205			107,230			(249,796	)		82,849
Less: Income from continuing operations		-			-			639			-			639
attributable to noncontrolling interests
Net income attributable to common		82,210			143,205			106,591			(249,796	)		82,210
shareholders
Other comprehensive income attributable to		6,607			4,621			6,259			(10,880	)		6,607
common shareholders
Comprehensive income attributable	$	88,817		$	147,826		$	112,850		$	(260,676	)	$	88,817
to common shareholders
	Six Months Ended June 30, 2013
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net revenues	$	-		$	502,868		$	469,952		$	(140,884	)	$	831,936
Cost of goods sold		-			296,436			267,895			(142,405	)		421,926
Gross profit		-			206,432			202,057			1,521			410,010
Selling, general and administrative expenses		31,827			126,492			85,090			(206	)		243,203
Research and development expenses		-			27,089			4,442			-			31,531
Restructuring and other impairment charges		-			9,278			12,843			-			22,121
Income (loss) from continuing operations before		(31,827	)		43,573			99,682			1,727			113,155
interest, and taxes
Interest expense		67,190			(42,144	)		3,572			-			28,618
Interest income		(3	)		-			(311	)		-			(314	)
Income (loss) from continuing operations		(99,014	)		85,717			96,421			1,727			84,851
before taxes
Taxes (benefit) on income (loss) from continuing		(35,746	)		27,980			20,739			776			13,749
operations
Equity in net income of consolidated subsidiaries		134,253			65,749			-			(200,002	)		-
Income from continuing operations		70,985			123,486			75,682			(199,051	)		71,102
Operating loss from discontinued operations		(2,152	)		-			368			-			(1,784	)
Taxes (benefit) on income (loss) from		(646	)		-			90			-			(556	)
discontinued operations
Loss from discontinued operations		(1,506	)		-			278			-			(1,228	)
Net income (loss)		69,479			123,486			75,960			(199,051	)		69,874
Less: Income from continuing operations		-			-			395			-			395
attributable to noncontrolling interests
Net income (loss) attributable to common		69,479			123,486			75,565			(199,051	)		69,479
shareholders
Other comprehensive income attributable to		(30,710	)		(33,350	)		(27,372	)		60,722			(30,710	)
common shareholders
Comprehensive income (loss) attributable	$	38,769		$	90,136		$	48,193		$	(138,329	)	$	38,769
to common shareholders
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING BALANCE SHEETS
	29-Jun-14
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	31,283		$	3,235		$	202,864		$	-		$	237,382
Accounts receivable, net		1,192			10,588			286,779			3,161			301,720
Accounts receivable from consolidated		40,046			2,750,172			263,688			(3,053,906	)		-
subsidiaries
Inventories, net		-			208,536			173,908			(25,977	)		356,467
Prepaid expenses and other current assets		13,916			5,175			19,295			-			38,386
Prepaid taxes		30,402			-			17,239			-			47,641
Deferred tax assets		20,136			19,051			11,314			(4	)		50,497
Assets held for sale		2,901			1,034			5,226			-			9,161
Total current assets		139,876			2,997,791			980,313			(3,076,726	)		1,041,254
Property, plant and equipment, net		3,939			193,017			146,452			-			343,408
Goodwill		-			703,258			670,098			-			1,373,356
Intangibles assets, net		-			722,652			511,253			-			1,233,905
Investments in affiliates		5,637,719			1,354,463			21,374			(7,012,091	)		1,465
Deferred tax assets		33,425			-			4,454			(36,935	)		944
Notes receivable and other amounts due from		963,322			978,447			-			(1,941,769	)		-
consolidated subsidiaries
Other assets		29,319			7,628			32,554			-			69,501
Total assets	$	6,807,600		$	6,957,256		$	2,366,498		$	(12,067,521	)	$	4,063,833
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	357,573		$	-		$	4,700		$	-		$	362,273
Accounts payable		5,582			34,483			33,468			-			73,533
Accounts payable to consolidated		2,661,371			190,790			201,745			(3,053,906	)		-
subsidiaries
Accrued expenses		17,280			18,855			43,905			-			80,040
Current portion of contingent consideration		-			2,959			-			-			2,959
Payroll and benefit-related liabilities		16,472			14,501			35,596			-			66,569
Accrued interest		9,989			-			2			-			9,991
Income taxes payable		-			-			21,817			-			21,817
Other current liabilities		635			29,153			5,524			(4	)		35,308
Total current liabilities		3,068,902			290,741			346,757			(3,053,910	)		652,490
Long-term borrowings		700,000			-			-			-			700,000
Deferred tax liabilities		-			491,345			63,022			(36,934	)		517,433
Pension and other postretirement benefit		50,913			33,555			17,726			-			102,194
liabilities
Noncurrent liability for uncertain tax positions		12,649			17,394			26,644			-			56,687
Notes payable and other amounts due from		973,020			872,248			104,242			(1,949,510	)		-
consolidated subsidiaries
Other liabilities		19,839			17,986			12,825			-			50,650
Total liabilities		4,825,323			1,723,269			571,216			(5,040,354	)		2,079,454
Total common shareholders' equity		1,982,277			5,233,987			1,793,180			(7,027,167	)		1,982,277
Noncontrolling interest		-			-			2,102			-			2,102
Total equity		1,982,277			5,233,987			1,795,282			(7,027,167	)		1,984,379
Total liabilities and equity	$	6,807,600		$	6,957,256		$	2,366,498		$	(12,067,521	)	$	4,063,833
	31-Dec-13
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	-		$	431,984
Accounts receivable, net		1,822			10,948			279,048			3,472			295,290
Accounts receivable from consolidated		42,865			2,623,314			214,469			(2,880,648	)		-
subsidiaries
Inventories, net		-			211,165			138,165			(15,709	)		333,621
Prepaid expenses and other current assets		15,200			6,870			17,740			-			39,810
Prepaid taxes		27,487			-			9,017			-			36,504
Deferred tax assets		20,218			22,472			10,230			(3	)		52,917
Assets held for sale		1,669			3,503			5,256			-			10,428
Total current assets		152,010			2,892,772			1,048,660			(2,892,888	)		1,200,554
Property, plant and equipment, net		14,189			188,455			123,256			-			325,900
Goodwill		-			797,671			556,532			-			1,354,203
Intangibles assets, net		-			962,243			293,354			-			1,255,597
Investments in affiliates		5,489,676			1,478,429			21,382			(6,987,772	)		1,715
Deferred tax assets		35,877			-			4,476			(39,410	)		943
Notes receivable and other amounts due from		1,049,344			873,105			14,169			(1,936,618	)		-
consolidated subsidiaries
Other assets		24,574			7,447			38,074			-			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	351,587		$	-		$	4,700		$	-		$	356,287
Accounts payable		2,194			45,802			23,971			-			71,967
Accounts payable to consolidated		2,644,296			147,957			88,395			(2,880,648	)		-
subsidiaries
Accrued expenses		15,569			21,120			38,179			-			74,868
Current portion of contingent consideration		-			4,131			-			-			4,131
Payroll and benefit-related liabilities		15,976			21,818			35,296			-			73,090
Accrued interest		8,720			-			5			-			8,725
Income taxes payable		-			-			23,821			-			23,821
Other current liabilities		9,646			7,517			5,072			(4	)		22,231
Total current liabilities		3,047,988			248,345			219,439			(2,880,652	)		635,120
Long-term borrowings		930,000			-			-			-			930,000
Deferred tax liabilities		-			496,228			57,896			(39,409	)		514,715
Pension and other postretirement benefit		57,406			33,777			18,315			-			109,498
liabilities
Noncurrent liability for uncertain tax positions		11,389			17,241			26,522			-			55,152
Notes payable and other amounts due from		785,476			957,451			197,173			(1,940,100	)		-
consolidated subsidiaries
Other liabilities		19,884			16,221			12,401			-			48,506
Total liabilities		4,852,143			1,769,263			531,746			(4,860,161	)		2,292,991
Total common shareholders' equity		1,913,527			5,430,859			1,565,668			(6,996,527	)		1,913,527
Noncontrolling interest		-			-			2,489			-			2,489
Total equity		1,913,527			5,430,859			1,568,157			(6,996,527	)		1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
	Six Months Ended June 29, 2014
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating	$	(49,306	)	$	277,376		$	(33,864	)	$	(74,045	)	$	120,161
activities from continuing operations
Cash Flows from Investing Activities of
Continuing Operations:
Expenditures for property, plant and equipment		(2,019	)		(14,080	)		(14,751	)		-			(30,850	)
Proceeds from sale of assets and investments		1,669			2,470			-			-			4,139
Payments for businesses and intangibles		-			-			(28,535	)		-			(28,535	)
acquired, net of cash acquired
Investments in affiliates		(60	)		-			-			-			(60	)
Intercompany dividends received		-			-			229,782			(229,782	)		-
Net cash used in investing activities		(410	)		(11,610	)		186,496			(229,782	)		(55,306	)
from continuing operations
Cash Flows from Financing Activities of
Continuing Operations:
Proceeds from long-term borrowings		250,000			-			-			-			250,000
Repayment of long-term borrowings		(480,000	)		-			-			-			(480,000	)
Debt issuance fees		(3,275	)		-			-			-			(3,275	)
Proceeds from share based  compensation		2,391			-			-			-			2,391
plans and the related tax impacts
Payments to noncontrolling interest shareholders					-			(1,094	)		-			(1,094	)
Dividends		(28,093	)		-			-			-			(28,093	)
Intercompany transactions		298,758			(277,031	)		(21,727	)		-			-
Intercompany dividends paid		-			-			(303,827	)		303,827			-
Net cash provided by (used in) financing		39,781			(277,031	)		(326,648	)		303,827			(260,071	)
activities from continuing operations
Cash Flows from Discontinued Operations:
Net cash used in operating activities		(1,531	)		-			-			-			(1,531	)
Net cash used in discontinued operations		(1,531	)		-			-			-			(1,531	)
Effect of exchange rate changes on cash and		-			-			2,145			-			2,145
cash equivalents
Net decrease in cash and cash equivalents		(11,466	)		(11,265	)		(171,871	)		-			(194,602	)
Cash and cash equivalents at the beginning of		42,749			14,500			374,735			-			431,984
the period
Cash and cash equivalents at the end of the	$	31,283		$	3,235		$	202,864		$	-		$	237,382
period
	Six Months Ended June 30, 2013
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating	$	(58,665	)	$	92,513		$	73,722		$	(51,327	)	$	56,243
activities from continuing operations
Cash Flows from Investing Activities of
Continuing Operations:
Expenditures for property, plant and equipment		(711	)		(28,617	)		(7,569	)		-			(36,897	)
Payments for businesses and intangibles		-			1,500			(38,454	)		-			(36,954	)
acquired, net of cash acquired
Investments in affiliates		(50	)		-			-			-			(50	)
Net cash used in investing activities		(761	)		(27,117	)		(46,023	)		-			(73,901	)
from continuing operations
Cash Flows from Financing Activities of
Continuing Operations:
Proceeds from share based compensation		3,892			-			-			-			3,892
plans and the related tax impacts
Payments to noncontrolling interest shareholders		-			-			(736	)		-			(736	)
Payments for contingent consideration		-			(7,922	)		(1,565	)		-			(9,487	)
Dividends		(27,944	)		-			-			-			(27,944	)
Intercompany transactions		41,548			(42,063	)		515			-			-
Intercompany dividends paid		-			(17,400	)		(33,927	)		51,327			-
Net cash provided by (used in)		17,496			(67,385	)		(35,713	)		51,327			(34,275	)
financing activities from
continuing operations
Cash Flows from Discontinued Operations:
Net cash used in operating activities		(837	)		-			(600	)		-			(1,437	)
Net cash used in discontinued operations		(837	)		-			(600	)		-			(1,437	)
Effect of exchange rate changes on cash and		-			-			(2,251	)		-			(2,251	)
cash equivalents
Net decrease in cash and cash equivalents		(42,767	)		(1,989	)		(10,865	)		-			(55,621	)
Cash and cash equivalents at the beginning of		70,860			1,989			264,190			-			337,039
the period
Cash and cash equivalents at the end of the	$	28,093		$	-		$	253,325		$	-		$	281,418
period

New_Accounting_Standards_Polic

New Accounting Standards (Policies)	6 Months Ended
	Jun. 29, 2014
New Accounting Pronouncements, Policy	'
	In April 2014, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of discontinued operations. Under the new guidance, only those disposals of components of an entity that represent a strategic shift that has or will have a major effect on an entity's operations and financial results will be reported as discontinued operations in an entity's financial statements. In addition, the new guidance requires additional disclosures for discontinued operations designed to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. The new guidance also requires disclosures regarding disposals of a significant component of an entity that does not qualify for discontinued operations reporting.This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014 with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the Company’s results of operations, cash flows or financial position.
	In May 2014, the FASB, in a joint effort with the International Accounting Standards Board, issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years.  Early application is not permitted. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows, and financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions_Tables

Acquisitions (Tables)	6 Months Ended
	Jun. 29, 2014
Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition	'
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo Healthcare acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	10,393
	Property, plant and equipment		306
	Customer lists intangible asset		9,335
	Goodwill		15,986
	Total assets acquired		36,020
	Liabilities
	Current liabilities		4,685
	Deferred tax liabilities		2,800
	Liabilities assumed		7,485
	Net assets acquired	$	28,535

Restructuring_and_Other_Impair1

Restructuring and Other Impairment Charges (Tables)	6 Months Ended
	Jun. 29, 2014
Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan	'
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the 2014 Manufacturing Footprint Realignment Plan:
		Total estimated amount expected to be incurred
	Type of cost
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.
Restructuring and Other Impairment Charges	'
	The restructuring and other impairment charges recognized for the three and six months ended June 29, 2014 and June 30, 2013 consisted of the following:
	Three Months Ended June 29, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	2014 Manufacturing footprint realignment	$	8,577		$	—		$	—		$	—	$	8,577
	2014 European restructuring plan		(566	)		—			305			49		(212	)
	2014 Restructuring charges		476			—			1,174			131		1,781
	LMA restructuring program		(29	)		(154	)		(2,759	)		—		(2,942	)
	2013 Restructuring charges		317			—			57			22		396
	2012 Restructuring charges		(9	)		34			—			—		25
	2011 Restructuring plan		—			(2	)		—			—		(2	)
	Total restructuring and other impairment charges	$	8,766		$	(122	)	$	(1,223	)	$	202	$	7,623
	Three Months Ended June 30, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	802		$	293		$	2,839		$	7	$	3,941
	2013 Restructuring charges		1,131			—			3,391			2,828		7,350
	2012 Restructuring charges		1,216			102			293			5		1,616
	2011 Restructuring plan		—			—			—			—		—
	2007 Arrow integration program		—			55			—			—		55
	Total restructuring and other impairment charges	$	3,149		$	450		$	6,523		$	2,840	$	12,962
	Six Months Ended June 29, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	2014 Manufacturing footprint realignment	$	8,577		$	—		$	—		$	—	$	8,577
	2014 European restructuring plan		7,752			—			305			49		8,106
	2014 Restructuring charges		476			—			1,174			131		1,781
	LMA restructuring program		(29	)		(112	)		(3,231	)		—		(3,372	)
	2013 Restructuring charges		485			—			57			22		564
	2012 Restructuring charges		(619	)		354			—			—		(265	)
	2011 Restructuring plan		—			12			—			—		12
	Total restructuring and other impairment charges	$	16,642		$	254		$	(1,695	)	$	202	$	15,403
	Six Months Ended June 30, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	2,826		$	374		$	3,281		$	115	$	6,596
	2013 Restructuring charges		1,552			—			3,391			2,887		7,830
	2012 Restructuring charges		2,666			102			293			5		3,066
	2007 Arrow integration program		—			135			—			—		135
			7,044			611			6,965			3,007		17,627
	Impairment charges		—			—			—			4,494		4,494
	Total restructuring and other impairment charges	$	7,044		$	611		$	6,965		$	7,501	$	22,121
Reporting Segment	'
Restructuring and Other Impairment Charges	'
	Restructuring and other impairment charges by reportable segment for the three and six months ended June 29, 2014 and June 30, 2013 are set forth in the following table:
		Three Months Ended						Six Months Ended
		29-Jun-14			30-Jun-13			29-Jun-14			30-Jun-13
		(Dollars in thousands)						(Dollars in thousands)
	Restructuring and other impairment charges
	Vascular North America	$	5,887		$	130		$	5,962		$	627
	Anesthesia/Respiratory North America		1,151			762			1,178			2,669
	Surgical North America		—			2,800			—			7,294
	EMEA		(1,575	)		7,913			6,315			9,207
	Asia		519			147			597			245
	OEM		—			588			—			588
	All other		1,641			622			1,351			1,491
	Total restructuring and other impairment charges	$	7,623		$	12,962		$	15,403		$	22,121
LMA Restructuring Program	'
Changes in Accrued Liability Associated with Restructuring Program	'
	A reconciliation of the changes in accrued liabilities associated with the LMA restructuring program from December 31, 2013 through June 29, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals (reversals)		(29	)		(112	)		(3,231	)		—		(3,372	)
	Cash payments		(494	)		(317	)		(70	)		—		(881	)
	Foreign currency translation		—			2			(1	)		1		2
	Balance at June 29, 2014	$	29		$	-		$	384		$	17	$	430

Inventories_Net_Tables

Inventories, Net (Tables)	6 Months Ended
	Jun. 29, 2014
Inventories, Net	'
	Inventories as of June 29, 2014 and December 31, 2013 consisted of the following:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Raw materials	$	74,790		$	70,209
	Work-in-process		59,412			53,672
	Finished goods		255,244			242,113
			389,446			365,994
	Less: Inventory reserve		(32,979	)		(32,373	)
	Inventories, net	$	356,467		$	333,621

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets, Net (Tables)	6 Months Ended
	Jun. 29, 2014
Changes in Carrying Amount of Goodwill, by Reporting Segment	'
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the six months ended June 29, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia		All			Total
		North America			Respiratory			North America								Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946	$	284,223		$	1,686,331
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
			254,517			60,122			250,506			373,417			136,946		278,695			1,354,203
	Goodwill related to		—			—			—			—			15,986		—			15,986
	acquisitions
	Translation adjustment		—			(82	)		—			(279	)		3,636		(108	)		3,167
	Balance as of June 29, 2014
	Goodwill		474,044			167,113			250,506			373,138			156,568		284,115			1,705,484
	Accumulated impairment		(219,527	)		(107,073	)		—			—			—		(5,528	)		(332,128	)
	losses
		$	254,517		$	60,040		$	250,506		$	373,138		$	156,568	$	278,587		$	1,373,356
Components of Intangible Assets	'
	The following table provides information as of June 29, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		June 29,			December 31,			June 29,			December 31,
		2014			2013			2014			2013
		(Dollars in thousands)
	Customer relationships	$	638,315		$	628,020		$	(183,363	)	$	(168,223	)
	In-process research and development		68,786			68,786			—			—
	Intellectual property		435,811			435,869			(133,795	)		(118,086	)
	Distribution rights		16,761			16,797			(14,726	)		(14,592	)
	Trade names		408,050			407,879			(2,089	)		(1,148	)
	Noncompete agreements		337			337			(182	)		(42	)
		$	1,568,060		$	1,557,688		$	(334,155	)	$	(302,091	)
Estimated Annual Amortization Expense	'
	Amortization expense related to intangible assets was $16.1 million and $12.1 million for the three months ended June 29, 2014 and June 30, 2013, respectively, and $32.1 million and $24.6 million for the six months ended June 29, 2014 and June 30, 2013, respectively.  Estimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014		$	33,000
	2015			55,500
	2016			54,500
	2017			54,000
	2018			53,500
	2019			51,000

Borrowings_Tables

Borrowings (Tables)	6 Months Ended
	Jun. 29, 2014
Components of Long-Term Debt	'
	The components of long-term debt at June 29, 2014 and December 31, 2013 are as follows:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 2.15% at June 29,	$	200,000		$	680,000
	2014, due 7/16/2018
	3.875% Convertible Senior Subordinated Notes		400,000			400,000
	6.875% Senior Subordinated Notes due 2019		250,000			250,000
	5.25% Senior Notes due 2024		250,000			-
	Total borrowings		1,100,000			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible		(42,427	)		(48,413	)
	Senior Subordinated Notes
			1,057,573			1,281,587
	Current portion of borrowings		(357,573	)		(351,587	)
		$	700,000		$	930,000
Fair Value of Long-Term Debt	'
	The carrying amount of long-term debt reported in the consolidated balance sheet as of June 29, 2014 is $1,057.6 million. The Company uses quoted market prices to estimate the fair value of its publicly traded debt. To estimate the fair value of debt for which there are no quoted market prices, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of June 29, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	968,108
	Level 2		457,051
	Total	$	1,425,159

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 29, 2014
Fair Values of Derivative Instruments Designated as Hedging Instruments	'
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of June 29, 2014 and December 31, 2013:
		June 29,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign exchange contracts:
	Prepaid expenses and other current assets	$	902		$	—
	Total asset derivatives	$	902		$	—
	Liability derivatives:
	Foreign exchange contracts:
	Other current liabilities	$	621		$	—
	Total liability derivatives	$	621		$	—
After Tax Gain/(Loss) Recognized in OCI	'
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three and six months ended June 29, 2014 and June 30, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		Three Months Ended						Six Months Ended
		June 29,			June 30,			June 29,		June 30,
		2014			2013			2014		2013
		(Dollars in thousands)
	Foreign exchange contracts	$	73		$	(192	)	$	143	$	(12	)
	Total	$	73		$	(192	)	$	143	$	(12	)
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	'
	Some of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided. Collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal, resulted in an increase in the allowance for doubtful accounts related to these countries. If the financial condition of these customers or the healthcare systems in these countries deteriorate such that the ability of an increasing number of customers to make payments is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal as a percentage of the Company’s net current and long-term accounts receivable at June 29, 2014 and December 31, 2013 are as follows:
		June 29,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.9 million and $7.9 million at June 29, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal(1)	$	95,653		$	97,852
	Percentage of total net current and long-term accounts receivable		30.8	%		31	%
	-1	The long-term portion of accounts receivable, net at June 29, 2014 and December 31, 2013 was $12.7 million and $17.6 million, respectively.

Fair_Value_Measurement_Tables

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 29, 2014
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	'
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of June 29, 2014 and December 31, 2013:
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		June 29,				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,535			$	6,535	$	—	$	—
	Derivative assets		902				—		902		—
	Derivative liabilities		621				—		621		—
	Contingent consideration liabilities		13,696				—		—		13,696
		Total carrying				Quoted prices in		Significant other		Significant
		value at				active markets		observable		unobservable
		December 31, 2013				(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150			$	6,150	$	—	$	—
	Contingent consideration liabilities		20,313				—		—		20,313
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the six months ended June 29, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations		(6,617	)
	Balance - June 29, 2014	$	13,696
Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities	'
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of June 29, 2014:
			Valuation Technique		Unobservable Input		Range (Weighted Average)
	Contingent consideration		Discounted cash flow		Discount rate		1.6%—10% (8.6%)
					Probability of payment		0%—100% (32.0%)

Changes_in_Shareholders_Equity1

Changes in Shareholders' Equity (Tables)	6 Months Ended
	Jun. 29, 2014
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	'
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended						Six Months Ended
		29-Jun-14			30-Jun-13			29-Jun-14			30-Jun-13
		(Shares in thousands)
	Basic		41,380			41,115			41,321			41,064
	Dilutive effect of share based awards		413			374			442			384
	Dilutive effect of 3.875% Convertible Notes and warrants		4,599			1,940			4,308			1,790
	Diluted		46,392			43,429			46,071			43,238
Change in Accumulated Other Comprehensive Income (Loss)	'
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the six months ended June 29, 2014 and June 30, 2013:
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2013	$	—		$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss)		233			(256	)		5,222			5,199
	before reclassifications
	Amounts reclassified from		(90	)		1,498			—			1,408
	accumulated other
	comprehensive  income (loss)
	Net current-period other		143			1,242			5,222			6,607
	comprehensive income
	Balance at June 29, 2014	$	143		$	(95,795	)	$	(8,596	)	$	(104,248	)
		Cash Flow Hedges			Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)	$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss)		362			(452	)		(32,654	)		(32,744	)
	before reclassifications
	Amounts reclassified from		(374	)		2,408			—			2,034
	accumulated other
	comprehensive income (loss)
	Net current-period other		(12	)		1,956			(32,654	)		(30,710	)
	comprehensive income (loss)
	Balance at June 30, 2013	$	(393	)	$	(125,301	)	$	(37,064	)	$	(162,758	)
Reclassification of Gain/Losses into Income/Expense, Net of Tax	'
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three and six months ended June 29, 2014 and June 30, 2013:
		Three Months Ended						Six Months Ended
		June 29,			June 30,			June 29,			June 30,
		2014			2013			2014			2013
		(Dollars in thousands)
	Gains and losses on foreign exchange contracts:
	Cost of goods sold	$	(52	)	$	(194	)	$	(129	)	$	(696	)
	Total before tax		(52	)		(194	)		(129	)		(696	)
	Tax expense		5			95			39			322
	Net of tax	$	(47	)	$	(99	)	$	(90	)	$	(374	)
	Amortization of pension and other postretirement
	benefit items:
	Actuarial losses/(gains) (1)	$	1,103		$	1,618		$	2,205		$	3,764
	Prior-service costs(1)		(6	)		(6	)		(11	)		(11	)
	Transition obligation(1)		—			1			-			2
	Total before tax		1,097			1,613			2,194			3,755
	Tax expense		(382	)		(660	)		(696	)		(1,347	)
	Net of tax	$	715		$	953		$	1,498		$	2,408
	Total reclassifications, net of tax	$	668		$	854		$	1,408		$	2,034
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_Income_from_Continuin1

Taxes on Income from Continuing Operations (Tables)	6 Months Ended
	Jun. 29, 2014
Effective Income Tax Rate	'
		Three Months Ended					Six Months Ended
		June 29,			June 30,		June 29,			June 30,
		2014			2013		2014			2013
	Effective income tax rate		17	%		12.30%		18.1	%		16.20%

Pension_and_Other_Postretireme1

Pension and Other Postretirement Benefits (Tables)	6 Months Ended
	Jun. 29, 2014
Net Benefit Cost of Pension and Postretirement Benefit Plans	'
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits				Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended				Six Months Ended						Six Months Ended
		June 29,			June 30,			June 29,		June 30,		June 29,			June 30,			June 29,		June 30,
		2014			2013			2014		2013		2014			2013			2014		2013
		(Dollars in thousands)
	Service cost	$	447		$	464		$	138	$	161	$	897		$	929		$	276	$	325
	Interest cost	$	4,486			4,142		$	596		542		8,969			8,281			1,193		1,541
	Expected return on plan assets	$	(6,264	)		(5,774	)	$	—		—		(12,524	)		(11,544	)		—		—
	Net amortization and deferral	$	1,070			1,414		$	27		202		2,141			2,824			53		932
	Net benefit expense (income)	$	(261	)	$	246		$	761	$	905	$	(517	)	$	490		$	1,522	$	2,798

Business_Segment_Information_T

Business Segment Information (Tables)	6 Months Ended
	Jun. 29, 2014
Segment Results	'
	The following tables present the Company’s segment results for the three and six months ended June 29, 2014 and June 30, 2013:
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Revenue
	Vascular North America	$	64,187		$	56,746		$	126,694		$	113,420
	Anesthesia/Respiratory North America		55,049			58,516			109,763			116,690
	Surgical North America		37,969			37,749			73,200			74,437
	EMEA		154,670			137,842			304,914			280,260
	Asia		62,539			50,409			112,142			92,777
	OEM		36,610			32,110			69,791			63,448
	All other		57,081			46,687			110,147			90,904
	Consolidated net revenues	$	468,105		$	420,059		$	906,651		$	831,936
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	9,988		$	6,326		$	19,381		$	11,352
	Anesthesia/Respiratory North America		6,293			9,264			11,980			14,942
	Surgical North America		14,366			13,651			24,914			27,313
	EMEA		30,080			21,226			56,961			44,468
	Asia		17,096			13,971			29,932			26,067
	OEM		8,296			7,734			14,900			14,094
	All other		10,355			9,507			20,121			11,522
	Total segment operating profit (1)		96,474			81,679			178,189			149,758
	Unallocated expenses (2)		(21,722	)		(17,928	)		(44,417	)		(36,603	)
	Income from continuing operations before	$	74,752		$	63,751		$	133,772		$	113,155
	Interest and taxes
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	8,066		$	6,875		$	15,921		$	13,434
	Anesthesia/Respiratory North America		3,708			2,874			8,136			6,715
	Surgical North America		1,666			2,678			4,035			5,232
	EMEA		9,673			6,843			18,610			13,994
	Asia		2,305			1,203			4,143			2,415
	OEM		1,608			1,213			3,064			2,361
	All other		5,376			3,933			9,906			7,809
	Consolidated depreciation and amortization	$	32,402		$	25,619		$	63,815		$	51,960
Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region	'
	The following table provides total net revenues for the three and six months ended June 29, 2014 and June 30, 2013 and total net property, plant and equipment by geographic region as of June 29, 2014 and December 31, 2013:
		Three Months Ended						Six Months Ended
		June 29, 2014			June 30, 2013			June 29, 2014			June 30, 2013
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	228,349		$	210,833		$	444,810		$	418,347
	Other Americas		15,188			14,527			29,958			28,678
	Germany		35,264			32,708			69,254			66,459
	Other Europe		138,929			108,068			273,713			214,754
	All other		50,375			53,923			88,916			103,698
		$	468,105		$	420,059		$	906,651		$	831,936
		29-Jun-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	198,266		$	203,985
	Other Americas		12,160			12,350
	Germany		12,129			12,135
	Other Europe		80,075			61,891
	All other		40,778			35,539
		$	343,408		$	325,900

Recovered_Sheet1

Condensed Consolidated Guarantor Financial Information (Tables)	6 Months Ended
	Jun. 29, 2014
Condensed Consolidating Financial Statement Adjustments	'
	The following table illustrates the increase/(decrease) to the previously reported amounts for the six months ended June 30, 2013:
		Six Months Ended June 30, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing	$	1,200		$	46,389		$	3,738		$	(51,327	)	$	—
	Operations
	Cash Flows from Financing Activities of Continuing
	Operations:
	Intercompany transactions		(1,200	)		(28,989	)		30,189			—			—
	Intercompany dividends paid		—			(17,400	)		(33,927	)		51,327			—
	Cash Flows from Financing Activities of Continuing	$	(1,200	)	$	(46,389	)	$	(3,738	)	$	51,327		$	—
	Operations
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended June 29, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	290,280		$	317,651		$	(139,826	)	$	468,105
	Cost of goods sold		-			176,028			177,009			(129,020	)		224,017
	Gross profit		-			114,252			140,642			(10,806	)		244,088
	Selling, general and administrative expenses		11,025			76,575			59,135			108			146,843
	Research and development expenses		-			12,885			1,985			-			14,870
	Restructuring and other impairment charges		-			8,679			(1,056	)		-			7,623
	Income (loss) from continuing operations		(11,025	)		16,113			80,578			(10,914	)		74,752
	before interest, and taxes
	Interest expense		35,155			(20,740	)		1,647			-			16,062
	Interest income		-			-			(146	)		-			(146	)
	Income (loss) from continuing operations		(46,180	)		36,853			79,077			(10,914	)		58,836
	before taxes
	Taxes (benefit) on income (loss) from continuing		(15,710	)		13,535			14,344			(2,163	)		10,006
	operations
	Equity in net income of consolidated subsidiaries		78,802			57,250			98			(136,150	)		-
	Income from continuing operations		48,332			80,568			64,831			(144,901	)		48,830
	Operating loss from discontinued operations		(1,594	)		-			-			-			(1,594	)
	Taxes (benefit) on income (loss) from		(514	)		-			45			-			(469	)
	discontinued operations
	Loss from discontinued operations		(1,080	)		-			(45	)		-			(1,125	)
	Net income		47,252			80,568			64,786			(144,901	)		47,705
	Less: Income from continuing operations		-			-			453			-			453
	attributable to noncontrolling interests
	Net income attributable to common		47,252			80,568			64,333			(144,901	)		47,252
	shareholders
	Other comprehensive income (loss) attributable		1,862			(2,607	)		(2,264	)		4,871			1,862
	to common shareholders
	Comprehensive income attributable	$	49,114		$	77,961		$	62,069		$	(140,030	)	$	49,114
	to common shareholders
		Three Months Ended June 30, 2013
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net revenues	$	-		$	248,012		$	239,147		$	(67,100	)	$	420,059
	Cost of goods sold		-			143,732			136,322			(69,485	)		210,569
	Gross profit		-			104,280			102,825			2,385			209,490
	Selling, general and administrative expenses		14,899			59,336			42,418			(400	)		116,253
	Research and development expenses		-			14,082			2,442			-			16,524
	Restructuring and other impairment charges		-			1,511			11,451			-			12,962
	Income (loss) from continuing operations before		(14,899	)		29,351			46,514			2,785			63,751
	interest, and taxes
	Interest expense		33,655			(21,017	)		1,787			-			14,425
	Interest income		3			-			(160	)		-			(157	)
	Income (loss) from continuing operations		(48,557	)		50,368			44,887			2,785			49,483
	before taxes
	Taxes (benefit) on income (loss) from continuing		(17,287	)		13,729			9,515			125			6,082
	operations
	Equity in net income of consolidated subsidiaries		74,433			31,599			-			(106,032	)		-
	Income from continuing operations		43,163			68,238			35,372			(103,372	)		43,401
	Operating loss from discontinued operations		(1,026	)		-			-			-			(1,026	)
	Taxes (benefit) on income (loss) from		(304	)		-			44			-			(260	)
	discontinued operations
	Loss from discontinued operations		(722	)		-			(44	)		-			(766	)
	Net income		42,441			68,238			35,328			(103,372	)		42,635
	Less: Income from continuing operations		-			-			194			-			194
	attributable to noncontrolling interests
	Net income attributable to common		42,441			68,238			35,134			(103,372	)		42,441
shareholders
Other comprehensive income (loss) attributable		(5,234	)		(1,224	)		(3,559	)		4,783			(5,234	)
to common shareholders
Comprehensive income attributable	$	37,207		$	67,014		$	31,575		$	(98,589	)	$	37,207
to common shareholders
	Six Months Ended June 29, 2014
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net revenues	$	-		$	552,705		$	566,088		$	(212,142	)	$	906,651
Cost of goods sold		-			328,396			314,882			(201,874	)		441,404
Gross profit		-			224,309			251,206			(10,268	)		465,247
Selling, general and administrative expenses		21,803			157,970			107,056			311			287,140
Research and development expenses		-			24,895			4,037			-			28,932
Restructuring and other impairment charges		-			8,491			6,912			-			15,403
Income (loss) from continuing operations		(21,803	)		32,953			133,201			(10,579	)		133,772
before interest, and taxes
Interest expense		68,881			(40,647	)		3,232			-			31,466
Interest income		-			-			(333	)		-			(333	)
Income (loss) from continuing operations		(90,684	)		73,600			130,302			(10,579	)		102,639
before taxes
Taxes (benefit) on income (loss) from continuing		(31,130	)		30,753			23,176			(4,259	)		18,540
operations
Equity in net income of consolidated subsidiaries		142,926			100,358			192			(243,476	)		-
Income from continuing operations		83,372			143,205			107,318			(249,796	)		84,099
Operating loss from discontinued operations		(1,619	)		-			-			-			(1,619	)
Taxes (benefit) on income (loss) from		(457	)		-			88			-			(369	)
discontinued operations
Loss from discontinued operations		(1,162	)		-			(88	)		-			(1,250	)
Net income		82,210			143,205			107,230			(249,796	)		82,849
Less: Income from continuing operations		-			-			639			-			639
attributable to noncontrolling interests
Net income attributable to common		82,210			143,205			106,591			(249,796	)		82,210
shareholders
Other comprehensive income attributable to		6,607			4,621			6,259			(10,880	)		6,607
common shareholders
Comprehensive income attributable	$	88,817		$	147,826		$	112,850		$	(260,676	)	$	88,817
to common shareholders
	Six Months Ended June 30, 2013
	Parent			Guarantor			Non-Guarantor						Condensed
	Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
	(Dollars in thousands)
Net revenues	$	-		$	502,868		$	469,952		$	(140,884	)	$	831,936
Cost of goods sold		-			296,436			267,895			(142,405	)		421,926
Gross profit		-			206,432			202,057			1,521			410,010
Selling, general and administrative expenses		31,827			126,492			85,090			(206	)		243,203
Research and development expenses		-			27,089			4,442			-			31,531
Restructuring and other impairment charges		-			9,278			12,843			-			22,121
Income (loss) from continuing operations before		(31,827	)		43,573			99,682			1,727			113,155
interest, and taxes
Interest expense		67,190			(42,144	)		3,572			-			28,618
Interest income		(3	)		-			(311	)		-			(314	)
Income (loss) from continuing operations		(99,014	)		85,717			96,421			1,727			84,851
before taxes
Taxes (benefit) on income (loss) from continuing		(35,746	)		27,980			20,739			776			13,749
operations
Equity in net income of consolidated subsidiaries		134,253			65,749			-			(200,002	)		-
Income from continuing operations		70,985			123,486			75,682			(199,051	)		71,102
Operating loss from discontinued operations		(2,152	)		-			368			-			(1,784	)
Taxes (benefit) on income (loss) from		(646	)		-			90			-			(556	)
discontinued operations
Loss from discontinued operations		(1,506	)		-			278			-			(1,228	)
Net income (loss)		69,479			123,486			75,960			(199,051	)		69,874
Less: Income from continuing operations		-			-			395			-			395
attributable to noncontrolling interests
Net income (loss) attributable to common		69,479			123,486			75,565			(199,051	)		69,479
shareholders
Other comprehensive income attributable to		(30,710	)		(33,350	)		(27,372	)		60,722			(30,710	)
common shareholders
Comprehensive income (loss) attributable	$	38,769		$	90,136		$	48,193		$	(138,329	)	$	38,769
to common shareholders
Condensed Consolidating Balance Sheets	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING BALANCE SHEETS
		29-Jun-14
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	31,283		$	3,235		$	202,864		$	-		$	237,382
	Accounts receivable, net		1,192			10,588			286,779			3,161			301,720
	Accounts receivable from consolidated		40,046			2,750,172			263,688			(3,053,906	)		-
	subsidiaries
	Inventories, net		-			208,536			173,908			(25,977	)		356,467
	Prepaid expenses and other current assets		13,916			5,175			19,295			-			38,386
	Prepaid taxes		30,402			-			17,239			-			47,641
	Deferred tax assets		20,136			19,051			11,314			(4	)		50,497
	Assets held for sale		2,901			1,034			5,226			-			9,161
	Total current assets		139,876			2,997,791			980,313			(3,076,726	)		1,041,254
	Property, plant and equipment, net		3,939			193,017			146,452			-			343,408
	Goodwill		-			703,258			670,098			-			1,373,356
	Intangibles assets, net		-			722,652			511,253			-			1,233,905
	Investments in affiliates		5,637,719			1,354,463			21,374			(7,012,091	)		1,465
	Deferred tax assets		33,425			-			4,454			(36,935	)		944
	Notes receivable and other amounts due from		963,322			978,447			-			(1,941,769	)		-
	consolidated subsidiaries
	Other assets		29,319			7,628			32,554			-			69,501
	Total assets	$	6,807,600		$	6,957,256		$	2,366,498		$	(12,067,521	)	$	4,063,833
	LIABILITIES AND EQUITY
	Current liabilities
	Current borrowings	$	357,573		$	-		$	4,700		$	-		$	362,273
	Accounts payable		5,582			34,483			33,468			-			73,533
	Accounts payable to consolidated		2,661,371			190,790			201,745			(3,053,906	)		-
	subsidiaries
	Accrued expenses		17,280			18,855			43,905			-			80,040
	Current portion of contingent consideration		-			2,959			-			-			2,959
	Payroll and benefit-related liabilities		16,472			14,501			35,596			-			66,569
	Accrued interest		9,989			-			2			-			9,991
	Income taxes payable		-			-			21,817			-			21,817
	Other current liabilities		635			29,153			5,524			(4	)		35,308
	Total current liabilities		3,068,902			290,741			346,757			(3,053,910	)		652,490
	Long-term borrowings		700,000			-			-			-			700,000
	Deferred tax liabilities		-			491,345			63,022			(36,934	)		517,433
	Pension and other postretirement benefit		50,913			33,555			17,726			-			102,194
	liabilities
	Noncurrent liability for uncertain tax positions		12,649			17,394			26,644			-			56,687
	Notes payable and other amounts due from		973,020			872,248			104,242			(1,949,510	)		-
	consolidated subsidiaries
	Other liabilities		19,839			17,986			12,825			-			50,650
	Total liabilities		4,825,323			1,723,269			571,216			(5,040,354	)		2,079,454
	Total common shareholders' equity		1,982,277			5,233,987			1,793,180			(7,027,167	)		1,982,277
	Noncontrolling interest		-			-			2,102			-			2,102
	Total equity		1,982,277			5,233,987			1,795,282			(7,027,167	)		1,984,379
	Total liabilities and equity	$	6,807,600		$	6,957,256		$	2,366,498		$	(12,067,521	)	$	4,063,833
		31-Dec-13
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	-		$	431,984
	Accounts receivable, net		1,822			10,948			279,048			3,472			295,290
	Accounts receivable from consolidated		42,865			2,623,314			214,469			(2,880,648	)		-
	subsidiaries
Inventories, net		-			211,165			138,165			(15,709	)		333,621
Prepaid expenses and other current assets		15,200			6,870			17,740			-			39,810
Prepaid taxes		27,487			-			9,017			-			36,504
Deferred tax assets		20,218			22,472			10,230			(3	)		52,917
Assets held for sale		1,669			3,503			5,256			-			10,428
Total current assets		152,010			2,892,772			1,048,660			(2,892,888	)		1,200,554
Property, plant and equipment, net		14,189			188,455			123,256			-			325,900
Goodwill		-			797,671			556,532			-			1,354,203
Intangibles assets, net		-			962,243			293,354			-			1,255,597
Investments in affiliates		5,489,676			1,478,429			21,382			(6,987,772	)		1,715
Deferred tax assets		35,877			-			4,476			(39,410	)		943
Notes receivable and other amounts due from		1,049,344			873,105			14,169			(1,936,618	)		-
consolidated subsidiaries
Other assets		24,574			7,447			38,074			-			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	351,587		$	-		$	4,700		$	-		$	356,287
Accounts payable		2,194			45,802			23,971			-			71,967
Accounts payable to consolidated		2,644,296			147,957			88,395			(2,880,648	)		-
subsidiaries
Accrued expenses		15,569			21,120			38,179			-			74,868
Current portion of contingent consideration		-			4,131			-			-			4,131
Payroll and benefit-related liabilities		15,976			21,818			35,296			-			73,090
Accrued interest		8,720			-			5			-			8,725
Income taxes payable		-			-			23,821			-			23,821
Other current liabilities		9,646			7,517			5,072			(4	)		22,231
Total current liabilities		3,047,988			248,345			219,439			(2,880,652	)		635,120
Long-term borrowings		930,000			-			-			-			930,000
Deferred tax liabilities		-			496,228			57,896			(39,409	)		514,715
Pension and other postretirement benefit		57,406			33,777			18,315			-			109,498
liabilities
Noncurrent liability for uncertain tax positions		11,389			17,241			26,522			-			55,152
Notes payable and other amounts due from		785,476			957,451			197,173			(1,940,100	)		-
consolidated subsidiaries
Other liabilities		19,884			16,221			12,401			-			48,506
Total liabilities		4,852,143			1,769,263			531,746			(4,860,161	)		2,292,991
Total common shareholders' equity		1,913,527			5,430,859			1,565,668			(6,996,527	)		1,913,527
Noncontrolling interest		-			-			2,489			-			2,489
Total equity		1,913,527			5,430,859			1,568,157			(6,996,527	)		1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
Condensed Consolidating Statements of Cash Flows	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
		Six Months Ended June 29, 2014
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating	$	(49,306	)	$	277,376		$	(33,864	)	$	(74,045	)	$	120,161
	activities from continuing operations
	Cash Flows from Investing Activities of
	Continuing Operations:
	Expenditures for property, plant and equipment		(2,019	)		(14,080	)		(14,751	)		-			(30,850	)
	Proceeds from sale of assets and investments		1,669			2,470			-			-			4,139
	Payments for businesses and intangibles		-			-			(28,535	)		-			(28,535	)
	acquired, net of cash acquired
	Investments in affiliates		(60	)		-			-			-			(60	)
	Intercompany dividends received		-			-			229,782			(229,782	)		-
	Net cash used in investing activities		(410	)		(11,610	)		186,496			(229,782	)		(55,306	)
	from continuing operations
	Cash Flows from Financing Activities of
	Continuing Operations:
	Proceeds from long-term borrowings		250,000			-			-			-			250,000
	Repayment of long-term borrowings		(480,000	)		-			-			-			(480,000	)
	Debt issuance fees		(3,275	)		-			-			-			(3,275	)
	Proceeds from share based  compensation		2,391			-			-			-			2,391
	plans and the related tax impacts
	Payments to noncontrolling interest shareholders					-			(1,094	)		-			(1,094	)
	Dividends		(28,093	)		-			-			-			(28,093	)
	Intercompany transactions		298,758			(277,031	)		(21,727	)		-			-
	Intercompany dividends paid		-			-			(303,827	)		303,827			-
	Net cash provided by (used in) financing		39,781			(277,031	)		(326,648	)		303,827			(260,071	)
	activities from continuing operations
	Cash Flows from Discontinued Operations:
	Net cash used in operating activities		(1,531	)		-			-			-			(1,531	)
	Net cash used in discontinued operations		(1,531	)		-			-			-			(1,531	)
	Effect of exchange rate changes on cash and		-			-			2,145			-			2,145
	cash equivalents
	Net decrease in cash and cash equivalents		(11,466	)		(11,265	)		(171,871	)		-			(194,602	)
	Cash and cash equivalents at the beginning of		42,749			14,500			374,735			-			431,984
	the period
	Cash and cash equivalents at the end of the	$	31,283		$	3,235		$	202,864		$	-		$	237,382
	period
		Six Months Ended June 30, 2013
		Parent			Guarantor			Non-Guarantor						Condensed
		Company			Subsidiaries			Subsidiaries			Eliminations			Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating	$	(58,665	)	$	92,513		$	73,722		$	(51,327	)	$	56,243
	activities from continuing operations
	Cash Flows from Investing Activities of
	Continuing Operations:
	Expenditures for property, plant and equipment		(711	)		(28,617	)		(7,569	)		-			(36,897	)
	Payments for businesses and intangibles		-			1,500			(38,454	)		-			(36,954	)
	acquired, net of cash acquired
	Investments in affiliates		(50	)		-			-			-			(50	)
	Net cash used in investing activities		(761	)		(27,117	)		(46,023	)		-			(73,901	)
	from continuing operations
	Cash Flows from Financing Activities of
	Continuing Operations:
	Proceeds from share based compensation		3,892			-			-			-			3,892
	plans and the related tax impacts
	Payments to noncontrolling interest shareholders		-			-			(736	)		-			(736	)
	Payments for contingent consideration		-			(7,922	)		(1,565	)		-			(9,487	)
	Dividends		(27,944	)		-			-			-			(27,944	)
	Intercompany transactions		41,548			(42,063	)		515			-			-
Intercompany dividends paid		-			(17,400	)		(33,927	)		51,327			-
Net cash provided by (used in)		17,496			(67,385	)		(35,713	)		51,327			(34,275	)
financing activities from
continuing operations
Cash Flows from Discontinued Operations:
Net cash used in operating activities		(837	)		-			(600	)		-			(1,437	)
Net cash used in discontinued operations		(837	)		-			(600	)		-			(1,437	)
Effect of exchange rate changes on cash and		-			-			(2,251	)		-			(2,251	)
cash equivalents
Net decrease in cash and cash equivalents		(42,767	)		(1,989	)		(10,865	)		-			(55,621	)
Cash and cash equivalents at the beginning of		70,860			1,989			264,190			-			337,039
the period
Cash and cash equivalents at the end of the	$	28,093		$	-		$	253,325		$	-		$	281,418
period

Basis_of_Presentation_Addition

Basis of Presentation - Additional Information (Detail) (Reclassifications, USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2013
Reclassifications	'
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]	'
Tax withholding obligations for share based compensation	$2.30

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013	Dec. 31, 2013
Business Acquisition [Line Items]	'	'	'	'	'
Fair value of the consideration at the date of acquisition	'	'	'	'	$307,000,000
Net revenues	468,105,000	420,059,000	906,651,000	831,936,000	'
Income from continuing operations before taxes	58,836,000	49,483,000	102,639,000	84,851,000	'
Mayo Healthcare Pty Limited	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Fair value of the consideration at the date of acquisition	28,500,000	'	28,500,000	'	'
Initial payment	'	'	29,000,000	'	'
Working capital adjustment related to acquisition	'	'	500,000	'	'
Transaction expenses	'	'	300,000	'	'
Net revenues	9,400,000	'	13,500,000	'	'
Income from continuing operations before taxes	$3,200,000	'	$3,800,000	'	'
Mayo Healthcare Pty Limited | Customer Lists	'	'	'	'	'
Business Acquisition [Line Items]	'	'	'	'	'
Useful life of intangible assets acquired, years	'	'	'10 years	'	'

Fair_Values_Determination_of_A

Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'
Goodwill	$1,373,356	$1,354,203
Mayo Healthcare Pty Limited	'	'
Business Acquisition [Line Items]	'	'
Current assets	10,393	'
Property, plant and equipment	306	'
Customer lists intangible asset	9,335	'
Goodwill	15,986	'
Total assets acquired	36,020	'
Current liabilities	4,685	'
Deferred tax liabilities	2,800	'
Liabilities assumed	7,485	'
Net assets acquired	$28,535	'

Restructuring_and_Other_Impair2

Restructuring and Other Impairment Charges - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

18 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 29, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Termination benefits

Contract Termination Costs

Contract Termination Costs

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2012 Restructuring Charges

Termination benefits

Termination benefits

Accelerated depreciation and other costs

Accelerated depreciation and other costs

Minimum

Minimum

Maximum

Maximum

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Minimum

Maximum

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Minimum

Maximum

Termination benefits

Termination benefits

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Termination benefits

Termination benefits

Restructuring Cost And Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected restructuring charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$42,000,000

$12,000,000

$53,000,000

$15,000,000

'

'

'

'

'

'

$8,000,000

$9,000,000

'

'

'

'

'

'

$2,000,000

$3,000,000

'

'

$11,000,000

'

'

'

'

'

'

'

'

'

'

'

Restructuring Costs Expected Cash Payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000,000

'

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

'

'

'

'

17,627,000

7,044,000

-3,231,000

6,965,000

8,577,000

8,577,000

8,577,000

8,577,000

900,000

900,000

'

'

'

'

-212,000

8,106,000

-566,000

7,752,000

305,000

305,000

'

'

1,781,000

1,781,000

476,000

476,000

1,174,000

1,174,000

'

'

396,000

7,350,000

564,000

7,830,000

10,800,000

317,000

1,131,000

485,000

1,552,000

57,000

3,391,000

57,000

3,391,000

'

Restructuring reserve

'

'

'

'

'

'

'

'

8,600,000

8,600,000

'

'

'

'

'

'

'

'

5,300,000

5,300,000

'

'

'

'

'

'

400,000

400,000

'

'

'

'

'

'

1,600,000

'

1,600,000

'

1,600,000

'

'

'

'

'

'

'

'

600,000

Restructuring expenses

'

'

'

'

'

'

'

'

9,500,000

9,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

In-process research and development impairment

$0

$0

$4,500,000

$0

$4,494,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_Current_Cost_Estima

Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan (Detail) (2014 Manufacturing Footprint Realignment, USD $)	6 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2014
Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	$42
Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	53
Termination benefits | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	12
Termination benefits | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	15
Facility closure and other exit costs | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	2	[1]
Facility closure and other exit costs | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	5	[1]
Accelerated depreciation charges | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	10
Accelerated depreciation charges | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	12
Other | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	18	[2]
Other | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	$21	[2]
[1]	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
[2]	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.

Reconciliation_of_Changes_in_A

Reconciliation of Changes in Accrued Liabilities Associated with Restructuring Program (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Subsequent accruals (reversals)	'	'	'	$17,627
LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Balance, beginning	'	'	4,681	'
Subsequent accruals (reversals)	-2,942	3,941	-3,372	6,596
Cash payments	'	'	-881	'
Foreign currency translation	'	'	2	'
Balance, ending	430	'	430	'
Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Subsequent accruals (reversals)	'	'	'	7,044
Termination Benefits | LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Balance, beginning	'	'	552	'
Subsequent accruals (reversals)	-29	802	-29	2,826
Cash payments	'	'	-494	'
Balance, ending	29	'	29	'
Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Subsequent accruals (reversals)	'	'	'	611
Facility Closure Costs | LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Balance, beginning	'	'	427	'
Subsequent accruals (reversals)	-154	293	-112	374
Cash payments	'	'	-317	'
Foreign currency translation	'	'	2	'
Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Subsequent accruals (reversals)	'	'	-3,231	6,965
Contract Termination Costs | LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Balance, beginning	'	'	3,686	'
Subsequent accruals (reversals)	-2,759	2,839	-3,231	3,281
Cash payments	'	'	-70	'
Foreign currency translation	'	'	-1	'
Balance, ending	384	'	384	'
Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Subsequent accruals (reversals)	'	'	'	3,007
Other Exit Costs | LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Balance, beginning	'	'	16	'
Subsequent accruals (reversals)	'	7	'	115
Foreign currency translation	'	'	1	'
Balance, ending	$17	'	$17	'

Restructuring_and_Other_Impair3

Restructuring and Other Impairment Charges (Detail) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

18 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

In Thousands, unless otherwise specified

Jun. 29, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 29, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2013

Termination Benefits

Termination Benefits

Termination Benefits

Termination Benefits

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Other Exit Costs

Other Exit Costs

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

LMA Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2012 Restructuring Program

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2011 Restructuring Plan

2007 Arrow Integration Program

2007 Arrow Integration Program

2007 Arrow Integration Program

2007 Arrow Integration Program

Termination Benefits

Termination Benefits

Termination Benefits

Termination Benefits

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Termination Benefits

Termination Benefits

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Termination Benefits

Termination Benefits

Termination Benefits

Termination Benefits

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Termination Benefits

Termination Benefits

Termination Benefits

Termination Benefits

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Other Exit Costs

Other Exit Costs

Termination Benefits

Termination Benefits

Termination Benefits

Termination Benefits

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Contract Termination Costs

Contract Termination Costs

Other Exit Costs

Other Exit Costs

Termination Benefits

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Contract Termination Costs

Other Exit Costs

Facility Closure Costs

Facility Closure Costs

Restructuring Cost And Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

'

'

'

'

$17,627

'

'

'

$7,044

'

'

'

$611

'

'

($3,231)

$6,965

'

'

'

$3,007

$8,577

$8,577

$8,577

$8,577

($212)

$8,106

($566)

$7,752

$305

$305

$49

$49

$1,781

$1,781

$476

$476

$1,174

$1,174

$131

$131

($2,942)

$3,941

($3,372)

$6,596

($29)

$802

($29)

$2,826

($154)

$293

($112)

$374

($2,759)

$2,839

($3,231)

$3,281

$7

$115

$396

$7,350

$564

$7,830

$10,800

$317

$1,131

$485

$1,552

$57

$3,391

$57

$3,391

$22

$2,828

$22

$2,887

$25

$1,616

($265)

$3,066

($9)

$1,216

($619)

$2,666

$34

$102

$354

$102

$293

$293

$5

$5

($2)

'

$12

'

($2)

'

$12

'

'

$55

$135

$55

$135

Restructuring and other impairment charges

7,623

12,962

'

15,403

22,121

8,766

3,149

16,642

7,044

-122

450

254

611

-1,223

6,523

-1,695

6,965

202

2,840

202

7,501

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges

$0

$0

$4,500

$0

$4,494

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,494

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring_and_Other_Impair4

Restructuring and Other Impairment Charges by Segment (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	$7,623	$12,962	$15,403	$22,121
Vascular North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	5,887	130	5,962	627
Anesthesia Respiratory North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	1,151	762	1,178	2,669
Surgical North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	'	2,800	'	7,294
EMEA	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	-1,575	7,913	6,315	9,207
Asia	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	519	147	597	245
OEM	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	'	588	'	588
All Other	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	$1,641	$622	$1,351	$1,491

Inventories_Net_Detail

Inventories, Net (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Raw materials	$74,790	$70,209
Work-in-process	59,412	53,672
Finished goods	255,244	242,113
Inventories, gross	389,446	365,994
Less: Inventory reserve	-32,979	-32,373
Inventories, net	$356,467	$333,621

Changes_in_Carrying_Amount_of_

Changes in Carrying Amount of Goodwill, by Reporting Segment (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Dec. 31, 2013
Goodwill [Line Items]	'	'
Goodwill gross	$1,705,484	$1,686,331
Accumulated impairment losses	-332,128	-332,128
Goodwill net	1,373,356	1,354,203
Goodwill related to acquisitions	15,986	'
Translation adjustment	3,167	'
Vascular North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	474,044	474,044
Accumulated impairment losses	-219,527	-219,527
Goodwill net	254,517	254,517
Anesthesia Respiratory North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	167,113	167,195
Accumulated impairment losses	-107,073	-107,073
Goodwill net	60,040	60,122
Translation adjustment	-82	'
Surgical North America	'	'
Goodwill [Line Items]	'	'
Goodwill gross	250,506	250,506
Goodwill net	250,506	250,506
EMEA	'	'
Goodwill [Line Items]	'	'
Goodwill gross	373,138	373,417
Goodwill net	373,138	373,417
Translation adjustment	-279	'
Asia	'	'
Goodwill [Line Items]	'	'
Goodwill gross	156,568	136,946
Goodwill net	156,568	136,946
Goodwill related to acquisitions	15,986	'
Translation adjustment	3,636	'
All Other	'	'
Goodwill [Line Items]	'	'
Goodwill gross	284,115	284,223
Accumulated impairment losses	-5,528	-5,528
Goodwill net	278,587	278,695
Translation adjustment	($108)	'

Components_of_Intangible_Asset

Components of Intangible Assets (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	$1,568,060	$1,557,688
Accumulated Amortization	-334,155	-302,091
In Process research and development	'	'
Finite Lived Intangible Assets [Line Items]	'	'
In-process research and development, gross carrying amount	68,786	68,786
Customer relationships	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	638,315	628,020
Accumulated Amortization	-183,363	-168,223
Intellectual property	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	435,811	435,869
Accumulated Amortization	-133,795	-118,086
Distribution rights	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	16,761	16,797
Accumulated Amortization	-14,726	-14,592
Trade names	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	408,050	407,879
Accumulated Amortization	-2,089	-1,148
Noncompete agreements	'	'
Finite Lived Intangible Assets [Line Items]	'	'
Gross Carrying Amount	337	337
Accumulated Amortization	($182)	($42)

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets, Net - Additional Information (Detail) (USD $)	3 Months Ended			6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Mar. 31, 2013	Jun. 29, 2014	Jun. 30, 2013
Finite Lived Intangible Assets [Line Items]	'	'	'	'	'
In-process research and development impairment	$0	$0	$4,500,000	$0	$4,494,000
Amortization expense of intangible assets	16,100,000	12,100,000	'	32,102,000	24,551,000
Semprus Technology	'	'	'	'	'
Finite Lived Intangible Assets [Line Items]	'	'	'	'	'
Net Assets	$41,000,000	'	'	$41,000,000	'

Estimated_Annual_Amortization_

Estimated Annual Amortization Expense (Detail) (USD $)	Jun. 29, 2014
In Thousands, unless otherwise specified
Finite Lived Intangible Assets [Line Items]	'
2014	$33,000
2015	55,500
2016	54,500
2017	54,000
2018	53,500
2019	$51,000

Components_of_LongTerm_Debt_De

Components of Long-Term Debt (Detail) (USD $)	Jun. 29, 2014	21-May-14	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'	'
Revolving credit facility, at a rate of 2.15% at June 29, 2014, due 7/16/2018	$200,000	'	$680,000
5.25% Senior Notes due 2024	250,000	250,000	'
Total borrowings	1,100,000	'	1,330,000
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes	-42,427	'	-48,413
Total long-term debt	1,057,573	'	1,281,587
Current portion of borrowings	-357,573	'	-351,587
Long-term borrowings	700,000	'	930,000
3.875% Convertible Senior Subordinated Notes	'	'	'
Debt Instrument [Line Items]	'	'	'
3.875% Convertible Senior Subordinated Notes	400,000	'	400,000
6.875% Senior Subordinated Notes due 2019	'	'	'
Debt Instrument [Line Items]	'	'	'
6.875% Senior Subordinated Notes due 2019	$250,000	'	$250,000

Components_of_LongTerm_Debt_Pa

Components of Long-Term Debt (Parenthetical) (Detail)	3 Months Ended	6 Months Ended			6 Months Ended	12 Months Ended	1 Months Ended	6 Months Ended
	Jun. 29, 2014	Jun. 29, 2014	Jun. 29, 2014	Dec. 31, 2013	Jun. 29, 2014	Dec. 31, 2013	21-May-14	Jun. 29, 2014
			3.875% Convertible Senior Subordinated Notes	3.875% Convertible Senior Subordinated Notes	6.875% Senior Subordinated Notes due 2019	6.875% Senior Subordinated Notes due 2019	5.25% Senior Notes due 2024	5.25% Senior Notes due 2024
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'
Revolving credit facility interest rate	2.15%	'	'	'	'	'	'	'
Debt instrument, stated interest rate	3.88%	3.88%	3.88%	3.88%	6.88%	6.88%	5.25%	5.25%
Debt instrument maturity date	'	16-Jul-18	1-Aug-17	'	1-Jun-19	1-Jun-19	15-Jun-24	15-Jun-24

Borrowings_Additional_Informat

Borrowings - Additional Information (Detail) (USD $)

6 Months Ended

1 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

Jun. 29, 2014

21-May-14

Dec. 31, 2013

21-May-14

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 31, 2013

Jun. 29, 2014

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

3.875% Convertible Senior Subordinated Notes

3.875% Convertible Senior Subordinated Notes

3.875% Convertible Senior Subordinated Notes

Minimum

Maximum

Redemption prior to June 15, 2019

Redemption prior to June 15, 2017

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

5.25% Senior Notes due 2024

$250,000,000

$250,000,000

'

'

'

'

'

'

'

'

'

'

Debt instrument, stated interest rate

3.88%

'

'

5.25%

5.25%

'

'

'

'

'

3.88%

3.88%

Debt instrument, interest payment commencing date

'

'

'

15-Dec-14

'

'

'

'

'

'

'

'

Debt instrument maturity date

16-Jul-18

'

'

15-Jun-24

15-Jun-24

'

'

'

'

'

'

1-Aug-17

Transaction fees

'

'

'

4,700,000

'

'

'

'

'

'

'

'

Proceed from senior Notes used to repay revolving line of credit

'

'

'

245,000,000

'

'

'

'

'

'

'

'

Percent of redemption price to principal amount any time on or after June 15, 2019

'

'

'

'

102.63%

'

'

'

'

'

'

'

Declining percent of redemption price to principal amount on June 15, 2022

'

'

'

'

'

0.88%

100.00%

'

'

'

'

'

Debt instrument, earliest date of redemption

'

'

'

'

15-Jun-19

'

'

'

'

'

'

'

Redemption price percentage

'

'

'

'

'

'

'

100.00%

105.25%

'

'

'

Make-whole premium as percentage of principal amount of 2024 Notes subject to redemption

'

'

'

'

'

'

'

1.00%

'

'

'

'

Basis spread

'

'

'

'

'

'

'

0.50%

'

'

'

'

Percent of principal amount of notes redeemable

'

'

'

'

'

'

'

'

35.00%

'

'

'

Convertible notes, threshold number of trading days to trigger conversion feature

'

'

'

'

'

'

'

'

'

'

'

'20 days

Convertible notes, threshold percentage of stock price trigger

'

'

'

'

'

'

'

'

'

130.00%

130.00%

'

Conversion price, per share

'

'

'

'

'

'

'

'

'

$61.32

'

'

Convertible notes, stock price trigger

'

'

'

'

'

'

'

'

'

$79.72

'

'

Total Long-term Debt

$1,057,573,000

'

$1,281,587,000

'

'

'

'

'

'

'

'

'

Fair_Value_of_LongTerm_Debt_De

Fair Value of Long-Term Debt (Detail) (USD $)	Jun. 29, 2014
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'
Fair value of long-term debt	$1,425,159
Level 1	'
Debt Instrument [Line Items]	'
Fair value of long-term debt	968,108
Level 2	'
Debt Instrument [Line Items]	'
Fair value of long-term debt	$457,051

Fair_Values_of_Derivative_Inst

Fair Values of Derivative Instruments Designated as Hedging Instruments (Detail) (USD $)	Jun. 29, 2014
In Thousands, unless otherwise specified
Derivatives Fair Value [Line Items]	'
Total asset derivatives	$902
Total liability derivatives	621
Prepaid Expenses and Other Current Assets | Foreign Exchange Contracts	'
Derivatives Fair Value [Line Items]	'
Total asset derivatives	902
Other Current Liabilities | Foreign Exchange Contracts	'
Derivatives Fair Value [Line Items]	'
Total liability derivatives	$621

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013	Dec. 31, 2013
Derivatives Fair Value [Line Items]	'	'	'	'	'
Total notional amount for all open foreign exchange contracts	$42,600,000	'	$42,600,000	'	$0
Amount of gains in accumulated other comprehensive income to be reclassified as expense to the statement of income	100,000	'	100,000	'	'
Allowance for Doubtful Accounts	10,200,000	'	10,200,000	'	10,700,000
Net revenues	468,105,000	420,059,000	906,651,000	831,936,000	'
Spain, Italy, Portugal, and Greece	'	'	'	'	'
Derivatives Fair Value [Line Items]	'	'	'	'	'
Net revenues	'	'	$79,600,000	$73,700,000	'

After_Tax_GainLoss_Reclassifie

After Tax (Gain)/Loss Reclassified from Accumulated Other Comprehensive Income into Income (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivatives qualifying as hedges, net of tax	$73	($192)	$143	($12)
Foreign Exchange Contracts	'	'	'	'
Derivative Instruments Gain Loss [Line Items]	'	'	'	'
Derivatives qualifying as hedges, net of tax	$73	($192)	$143	($12)

Aggregate_Accounts_Receivable_

Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts (Detail) (Spain, Italy, Portugal, and Greece, USD $)	6 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014		Dec. 31, 2013
Spain, Italy, Portugal, and Greece	'		'
Accounts Notes And Loans Receivable [Line Items]	'		'
Current and long-term accounts receivable, net	$95,653	[1]	$97,852	[1]
Percentage of total net current and long-term accounts receivable	30.80%		31.00%
[1]	The long-term portion of accounts receivable, net at June 29, 2014 and December 31, 2013 was $12.7 million and $17.6 million, respectively.

Aggregate_Accounts_Receivable_1

Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts (Parenthetical) (Detail) (Spain, Italy, Portugal, and Greece, USD $)	Jun. 29, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Spain, Italy, Portugal, and Greece	'	'
Accounts Notes And Loans Receivable [Line Items]	'	'
Current and long-term accounts receivable, allowances	$8.90	$7.90
Long-term portion of accounts receivable, net	$12.70	$17.60

Financial_Assets_and_Liabiliti

Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	$6,535	$6,150
Derivative assets	902	'
Derivative liabilities	621	'
Contingent consideration liabilities	13,696	20,313
Level 1	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	6,535	6,150
Derivative assets	'	'
Derivative liabilities	'	'
Contingent consideration liabilities	'	'
Level 2	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	'	'
Derivative assets	902	'
Derivative liabilities	621	'
Contingent consideration liabilities	'	'
Significant Unobservable Inputs (Level 3)	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	'	'
Derivative assets	'	'
Derivative liabilities	'	'
Contingent consideration liabilities	$13,696	$20,313

Reconciliation_of_Changes_in_L

Reconciliation of Changes in Level Three Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]	'	'	'	'
Beginning balance	'	'	$20,313	'
Revaluations	-4,400	-6,600	-6,617	-8,100
Ending balance	$13,696	'	$13,696	'

Fair_Value_Measurement_Additio

Fair Value Measurement - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Fair Value Measurements [Line Items]	'	'	'	'
Reversal of contingent consideration	$4,400,000	$6,600,000	$6,617,000	$8,100,000
Contingent consideration	13,700,000	'	13,700,000	'
Current contingent consideration	3,000,000	'	3,000,000	'
Other liabilities	10,700,000	'	10,700,000	'
Minimum	'	'	'	'
Fair Value Measurements [Line Items]	'	'	'	'
Fair value of contingent consideration liability associated with future milestone	0	'	0	'
Maximum	'	'	'	'
Fair Value Measurements [Line Items]	'	'	'	'
Fair value of contingent consideration liability associated with future milestone	$56,500,000	'	$56,500,000	'

Valuation_Technique_and_Inputs

Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities (Detail)	6 Months Ended
	Jun. 29, 2014
Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	8.60%
Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	32.00%
Minimum | Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	1.60%
Minimum | Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	0.00%
Maximum | Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	10.00%
Maximum | Probability of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	100.00%

Changes_in_Shareholders_Equity2

Changes in Shareholder's Equity - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
In Millions, except Per Share data, unless otherwise specified	Jun. 30, 2007	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Shareholders Equity [Line Items]	'	'	'	'	'
Repurchase of outstanding common stock, authorized amount	$300	'	'	'	'
Per share market price of common stock	'	$61.32	'	$61.32	'
Strike price of warrants	'	'	'	$74.65	$74.65
Conversion of convertible notes, shares issued upon conversion	'	1.9	0.4	1.7	0.3
Stock Option	'	'	'	'	'
Shareholders Equity [Line Items]	'	'	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	6.4	7.9	6.5	7.9
Convertible Note	'	'	'	'	'
Shareholders Equity [Line Items]	'	'	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	2.7	1.5	2.6	1.4

Reconciliation_of_Basic_to_Dil

Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding (Detail)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Schedule Of Earnings Per Share Basic And Diluted By Common Class [Line Items]	'	'	'	'
Basic	41,380	41,115	41,321	41,064
Dilutive effect of share based awards	413	374	442	384
Dilutive effect of 3.875% Convertible Notes and warrants	4,599	1,940	4,308	1,790
Diluted	46,392	43,429	46,071	43,238

Reconciliation_of_Basic_to_Dil1

Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding (Parenthetical) (Detail)	Jun. 29, 2014
Schedule Of Earnings Per Share Basic And Diluted By Common Class [Line Items]	'
Debt instrument, stated interest rate	3.88%

Change_in_Accumulated_Other_Co

Change in Accumulated Other Comprehensive Income (Loss), Net of tax (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	($110,855)	($132,048)
Other comprehensive income (loss) before reclassifications	5,199	-32,744
Amounts reclassified from accumulated other comprehensive income (loss)	1,408	2,034
Net current-period other comprehensive income (loss)	6,607	-30,710
Ending balance, accumulated other comprehensive income (loss), net of tax	-104,248	-162,758
Cash Flow Hedges	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	'	-381
Other comprehensive income (loss) before reclassifications	233	362
Amounts reclassified from accumulated other comprehensive income (loss)	-90	-374
Net current-period other comprehensive income (loss)	143	-12
Ending balance, accumulated other comprehensive income (loss), net of tax	143	-393
Pension and Other Postretirement Benefits Plans	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	-97,037	-127,257
Other comprehensive income (loss) before reclassifications	-256	-452
Amounts reclassified from accumulated other comprehensive income (loss)	1,498	2,408
Net current-period other comprehensive income (loss)	1,242	1,956
Ending balance, accumulated other comprehensive income (loss), net of tax	-95,795	-125,301
Foreign Currency Translation Adjustment	'	'
Accumulated Other Comprehensive Income Loss [Line Items]	'	'
Beginning balance, accumulated other comprehensive income (loss), net of tax	-13,818	-4,410
Other comprehensive income (loss) before reclassifications	5,222	-32,654
Net current-period other comprehensive income (loss)	5,222	-32,654
Ending balance, accumulated other comprehensive income (loss), net of tax	($8,596)	($37,064)

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss) into Income Expense (Detail) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014		Jun. 30, 2013		Jun. 29, 2014		Jun. 30, 2013
Accumulated Other Comprehensive Income Loss [Line Items]	'		'		'		'
Cost of goods sold	($224,017)		($210,569)		($441,404)		($421,926)
Income from continuing operations before taxes	58,836		49,483		102,639		84,851
Tax expense (benefit)	10,006		6,082		18,540		13,749
Net of tax	48,830		43,401		84,099		71,102
Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'		'		'
Total reclassifications, net of tax	668		854		1,408		2,034
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'		'		'
Income from continuing operations before taxes	-52		-194		-129		-696
Tax expense (benefit)	5		95		39		322
Net of tax	-47		-99		-90		-374
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges | Commodity Contract | Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'		'		'
Cost of goods sold	-52		-194		-129		-696
Pension and Other Postretirement Benefits Plans | Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'
Accumulated Other Comprehensive Income Loss [Line Items]	'		'		'		'
Income from continuing operations before taxes	1,097		1,613		2,194		3,755
Tax expense (benefit)	-382		-660		-696		-1,347
Net of tax	715		953		1,498		2,408
Actuarial losses/(gains)	1,103	[1]	1,618	[1]	2,205	[1]	3,764	[1]
Prior-service costs	-6	[1]	-6	[1]	-11	[1]	-11	[1]
Transition obligation	'		$1	[1]	'		$2	[1]
[1]	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Effective_Income_Tax_Rate_Deta

Effective Income Tax Rate (Detail)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Income Taxes [Line Items]	'	'	'	'
Effective income tax rate	17.00%	12.30%	18.10%	16.20%

Taxes_on_Income_from_Continuin2

Taxes on Income from Continuing Operations - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Income Taxes [Line Items]	'	'	'	'
Effective income tax rate	17.00%	12.30%	18.10%	16.20%

Net_Benefit_Cost_of_Pension_an

Net Benefit Cost of Pension and Postretirement Benefit Plans (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Pension	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	$447	$464	$897	$929
Interest cost	4,486	4,142	8,969	8,281
Expected return on plan assets	-6,264	-5,774	-12,524	-11,544
Net amortization and deferral	1,070	1,414	2,141	2,824
Net benefit expense (income)	-261	246	-517	490
Other Postretirement Benefits	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	138	161	276	325
Interest cost	596	542	1,193	1,541
Net amortization and deferral	27	202	53	932
Net benefit expense (income)	$761	$905	$1,522	$2,798

Pension_and_Other_Postretireme2

Pension and Other Postretirement Benefits - Additional Information (Detail) (USD $)	3 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jun. 29, 2014	Jun. 29, 2014
Defined Benefit Plans And Other Postretirement Benefit Plans Table Text Block [Line Items]	'	'
Expected employer contribution for year 2014	'	$9.40
Employer contribution to pension plan	$2.30	$4.70

Recovered_Sheet2

Commitments and Contingent Liabilities - Additional Information (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013	Jun. 29, 2014	Jun. 29, 2014	Jun. 29, 2014	Dec. 31, 2013	Jun. 29, 2014	Dec. 31, 2013	Jun. 29, 2014	Jun. 29, 2014
In Millions, unless otherwise specified			Minimum	Maximum	Accrued Liabilities	Accrued Liabilities	Other Liability	Other Liability	Property, Plant and Equipment	Property, Plant and Equipment
										Build To Suit Lease
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Estimated fair value of the costs to construct buildings	'	'	'	'	'	'	'	'	$24.80	$28.30
Expected construction completion year	'	'	'	'	'	'	'	'	'	'2014-10
Lease commencement date	'	'	'	'	'	'	'	'	'	1-Sep-13
Waste disposed accrued liability	'	'	'	'	2.2	2.5	5.4	5.8	'	'
Time-frame over which the accrued amounts may be paid out, in years	'	'	'15 years	'20 years	'	'	'	'	'	'
Contingency reserve for litigation	$5	$6.80	'	'	'	'	'	'	'	'

Segment_Result_Additional_Info

Segment Result - Additional Information (Detail)	6 Months Ended
	Jun. 29, 2014
	Segment
Revenues From External Customers And Long Lived Assets [Line Items]	'
Number of Reportable Segments	6

Segment_Result_Detail

Segment Result (Detail) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014		Jun. 30, 2013		Jun. 29, 2014		Jun. 30, 2013
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	$468,105		$420,059		$906,651		$831,936
Operating Profit	74,752		63,751		133,772		113,155
Depreciation and Amortization	32,402		25,619		63,815		51,960
Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	96,474	[1]	81,679	[1]	178,189	[1]	149,758	[1]
Unallocated expenses	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	-21,722	[2]	-17,928	[2]	-44,417	[2]	-36,603	[2]
Vascular North America	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	64,187		56,746		126,694		113,420
Depreciation and Amortization	8,066		6,875		15,921		13,434
Vascular North America | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	9,988		6,326		19,381		11,352
Anesthesia Respiratory North America	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	55,049		58,516		109,763		116,690
Depreciation and Amortization	3,708		2,874		8,136		6,715
Anesthesia Respiratory North America | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	6,293		9,264		11,980		14,942
Surgical North America	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	37,969		37,749		73,200		74,437
Depreciation and Amortization	1,666		2,678		4,035		5,232
Surgical North America | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	14,366		13,651		24,914		27,313
EMEA	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	154,670		137,842		304,914		280,260
Depreciation and Amortization	9,673		6,843		18,610		13,994
EMEA | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	30,080		21,226		56,961		44,468
Asia	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	62,539		50,409		112,142		92,777
Depreciation and Amortization	2,305		1,203		4,143		2,415
Asia | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	17,096		13,971		29,932		26,067
OEM	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	36,610		32,110		69,791		63,448
Depreciation and Amortization	1,608		1,213		3,064		2,361
OEM | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	8,296		7,734		14,900		14,094
All Other	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Revenue	57,081		46,687		110,147		90,904
Depreciation and Amortization	5,376		3,933		9,906		7,809
All Other | Operating Segments	'		'		'		'
Revenues From External Customers And Long Lived Assets [Line Items]	'		'		'		'
Operating Profit	$10,355		$9,507		$20,121		$11,522
[1]	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses.
[2]	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.

Total_Net_Revenues_and_Total_N

Total Net Revenues and Total Net Property, Plant and Equipment by Geographic Region (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013	Dec. 31, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	$468,105	$420,059	$906,651	$831,936	'
Property, plant and equipment, net	343,408	'	343,408	'	325,900
United States	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	228,349	210,833	444,810	418,347	'
Property, plant and equipment, net	198,266	'	198,266	'	203,985
Other Americas	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	15,188	14,527	29,958	28,678	'
Property, plant and equipment, net	12,160	'	12,160	'	12,350
Germany	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	35,264	32,708	69,254	66,459	'
Property, plant and equipment, net	12,129	'	12,129	'	12,135
Other Europe	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	138,929	108,068	273,713	214,754	'
Property, plant and equipment, net	80,075	'	80,075	'	61,891
All Other	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Net revenues	50,375	53,923	88,916	103,698	'
Property, plant and equipment, net	$40,778	'	$40,778	'	$35,539

Condensed_Consolidated_Guarant1

Condensed Consolidated Guarantor Financial Information - Additional Information (Detail) (USD $)	Jun. 29, 2014	Jun. 26, 2011
In Thousands, unless otherwise specified		6.875% Senior Subordinated Notes due 2019
Condensed Financial Statements Captions [Line Items]	'	'
Senior subordinated notes	'	$250,000
Debt instrument, stated interest rate	3.88%	6.88%
Ownership percentage of subsidiaries	100.00%	'

Adjustments_to_Condensed_Conso

Adjustments to Condensed Consolidating Statements of Cash Flows within Guarantor Financial Information (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013
Cash Flows from Operating Activities of Continuing Operations	$120,161	$56,243
Cash Flows from Financing Activities of Continuing Operations:	'	'
Cash Flows from Financing Activities of Continuing Operations	-260,071	-34,275
Consolidation, Eliminations	'	'
Cash Flows from Operating Activities of Continuing Operations	-74,045	-51,327
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany dividends paid	303,827	51,327
Cash Flows from Financing Activities of Continuing Operations	303,827	51,327
Scenario, Adjustment | Consolidation, Eliminations	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany dividends paid	'	51,327
Scenario, Adjustment | Before Adjustment | Consolidation, Eliminations	'	'
Cash Flows from Operating Activities of Continuing Operations	'	-51,327
Scenario, Adjustment | After Adjustment | Consolidation, Eliminations	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Cash Flows from Financing Activities of Continuing Operations	'	51,327
Parent Company	'	'
Cash Flows from Operating Activities of Continuing Operations	-49,306	-58,665
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	298,758	41,548
Cash Flows from Financing Activities of Continuing Operations	39,781	17,496
Parent Company | Scenario, Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	'	-1,200
Parent Company | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	1,200
Parent Company | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Cash Flows from Financing Activities of Continuing Operations	'	-1,200
Guarantor Subsidiaries	'	'
Cash Flows from Operating Activities of Continuing Operations	277,376	92,513
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	-277,031	-42,063
Intercompany dividends paid	'	-17,400
Cash Flows from Financing Activities of Continuing Operations	-277,031	-67,385
Guarantor Subsidiaries | Scenario, Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	'	-28,989
Intercompany dividends paid	'	-17,400
Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	46,389
Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Cash Flows from Financing Activities of Continuing Operations	'	-46,389
Non-Guarantor Subsidiaries	'	'
Cash Flows from Operating Activities of Continuing Operations	-33,864	73,722
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	-21,727	515
Intercompany dividends paid	-303,827	-33,927
Cash Flows from Financing Activities of Continuing Operations	-326,648	-35,713
Non-Guarantor Subsidiaries | Scenario, Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	'	30,189
Intercompany dividends paid	'	-33,927
Non-Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Cash Flows from Operating Activities of Continuing Operations	'	3,738
Non-Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Cash Flows from Financing Activities of Continuing Operations	'	($3,738)

Condensed_Consolidating_Statem

Condensed Consolidating Statements of Income (Loss) and Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013	Jun. 29, 2014	Jun. 30, 2013
Condensed Income Statements Captions [Line Items]	'	'	'	'
Net revenues	$468,105	$420,059	$906,651	$831,936
Cost of goods sold	224,017	210,569	441,404	421,926
Gross profit	244,088	209,490	465,247	410,010
Selling, general and administrative expenses	146,843	116,253	287,140	243,203
Research and development expenses	14,870	16,524	28,932	31,531
Restructuring and other impairment charges	7,623	12,962	15,403	22,121
Income (loss) from continuing operations before interest, and taxes	74,752	63,751	133,772	113,155
Interest expense	16,062	14,425	31,466	28,618
Interest income	-146	-157	-333	-314
Income (loss) from continuing operations before taxes	58,836	49,483	102,639	84,851
Tax expense (benefit)	10,006	6,082	18,540	13,749
Income from continuing operations	48,830	43,401	84,099	71,102
Operating loss from discontinued operations	-1,594	-1,026	-1,619	-1,784
Taxes (benefit) on income (loss) from discontinued operations	-469	-260	-369	-556
Loss from discontinued operations	-1,125	-766	-1,250	-1,228
Net income	47,705	42,635	82,849	69,874
Less: Income from continuing operations attributable to noncontrolling interests	453	194	639	395
Net income attributable to common shareholders	47,252	42,441	82,210	69,479
Other comprehensive income (loss) attributable to common shareholders	1,862	-5,234	6,607	-30,710
Comprehensive income attributable to common shareholders	49,114	37,207	88,817	38,769
Consolidation, Eliminations	'	'	'	'
Condensed Income Statements Captions [Line Items]	'	'	'	'
Net revenues	-139,826	-67,100	-212,142	-140,884
Cost of goods sold	-129,020	-69,485	-201,874	-142,405
Gross profit	-10,806	2,385	-10,268	1,521
Selling, general and administrative expenses	108	-400	311	-206
Income (loss) from continuing operations before interest, and taxes	-10,914	2,785	-10,579	1,727
Income (loss) from continuing operations before taxes	-10,914	2,785	-10,579	1,727
Tax expense (benefit)	-2,163	125	-4,259	776
Equity in net income of consolidated subsidiaries	-136,150	-106,032	-243,476	-200,002
Income from continuing operations	-144,901	-103,372	-249,796	-199,051
Net income	-144,901	-103,372	-249,796	-199,051
Net income attributable to common shareholders	-144,901	-103,372	-249,796	-199,051
Other comprehensive income (loss) attributable to common shareholders	4,871	4,783	-10,880	60,722
Comprehensive income attributable to common shareholders	-140,030	-98,589	-260,676	-138,329
Parent Company	'	'	'	'
Condensed Income Statements Captions [Line Items]	'	'	'	'
Selling, general and administrative expenses	11,025	14,899	21,803	31,827
Income (loss) from continuing operations before interest, and taxes	-11,025	-14,899	-21,803	-31,827
Interest expense	35,155	33,655	68,881	67,190
Interest income	'	3	'	-3
Income (loss) from continuing operations before taxes	-46,180	-48,557	-90,684	-99,014
Tax expense (benefit)	-15,710	-17,287	-31,130	-35,746
Equity in net income of consolidated subsidiaries	78,802	74,433	142,926	134,253
Income from continuing operations	48,332	43,163	83,372	70,985
Operating loss from discontinued operations	-1,594	-1,026	-1,619	-2,152
Taxes (benefit) on income (loss) from discontinued operations	-514	-304	-457	-646
Loss from discontinued operations	-1,080	-722	-1,162	-1,506
Net income	47,252	42,441	82,210	69,479
Net income attributable to common shareholders	47,252	42,441	82,210	69,479
Other comprehensive income (loss) attributable to common shareholders	1,862	-5,234	6,607	-30,710
Comprehensive income attributable to common shareholders	49,114	37,207	88,817	38,769
Guarantor Subsidiaries	'	'	'	'
Condensed Income Statements Captions [Line Items]	'	'	'	'
Net revenues	290,280	248,012	552,705	502,868
Cost of goods sold	176,028	143,732	328,396	296,436
Gross profit	114,252	104,280	224,309	206,432
Selling, general and administrative expenses	76,575	59,336	157,970	126,492
Research and development expenses	12,885	14,082	24,895	27,089
Restructuring and other impairment charges	8,679	1,511	8,491	9,278
Income (loss) from continuing operations before interest, and taxes	16,113	29,351	32,953	43,573
Interest expense	-20,740	-21,017	-40,647	-42,144
Income (loss) from continuing operations before taxes	36,853	50,368	73,600	85,717
Tax expense (benefit)	13,535	13,729	30,753	27,980
Equity in net income of consolidated subsidiaries	57,250	31,599	100,358	65,749
Income from continuing operations	80,568	68,238	143,205	123,486
Net income	80,568	68,238	143,205	123,486
Net income attributable to common shareholders	80,568	68,238	143,205	123,486
Other comprehensive income (loss) attributable to common shareholders	-2,607	-1,224	4,621	-33,350
Comprehensive income attributable to common shareholders	77,961	67,014	147,826	90,136
Non-Guarantor Subsidiaries	'	'	'	'
Condensed Income Statements Captions [Line Items]	'	'	'	'
Net revenues	317,651	239,147	566,088	469,952
Cost of goods sold	177,009	136,322	314,882	267,895
Gross profit	140,642	102,825	251,206	202,057
Selling, general and administrative expenses	59,135	42,418	107,056	85,090
Research and development expenses	1,985	2,442	4,037	4,442
Restructuring and other impairment charges	-1,056	11,451	6,912	12,843
Income (loss) from continuing operations before interest, and taxes	80,578	46,514	133,201	99,682
Interest expense	1,647	1,787	3,232	3,572
Interest income	-146	-160	-333	-311
Income (loss) from continuing operations before taxes	79,077	44,887	130,302	96,421
Tax expense (benefit)	14,344	9,515	23,176	20,739
Equity in net income of consolidated subsidiaries	98	'	192	'
Income from continuing operations	64,831	35,372	107,318	75,682
Operating loss from discontinued operations	'	'	'	368
Taxes (benefit) on income (loss) from discontinued operations	45	44	88	90
Loss from discontinued operations	-45	-44	-88	278
Net income	64,786	35,328	107,230	75,960
Less: Income from continuing operations attributable to noncontrolling interests	453	194	639	395
Net income attributable to common shareholders	64,333	35,134	106,591	75,565
Other comprehensive income (loss) attributable to common shareholders	-2,264	-3,559	6,259	-27,372
Comprehensive income attributable to common shareholders	$62,069	$31,575	$112,850	$48,193

Condensed_Consolidating_Balanc

Condensed Consolidating Balance Sheets (Detail) (USD $)	Jun. 29, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'	'	'
Cash and cash equivalents	$237,382	$431,984	$281,418	$337,039
Accounts receivable, net	301,720	295,290	'	'
Inventories, net	356,467	333,621	'	'
Prepaid expenses and other current assets	38,386	39,810	'	'
Prepaid taxes	47,641	36,504	'	'
Deferred tax assets	50,497	52,917	'	'
Assets held for sale	9,161	10,428	'	'
Total current assets	1,041,254	1,200,554	'	'
Property, plant and equipment, net	343,408	325,900	'	'
Goodwill	1,373,356	1,354,203	'	'
Intangible assets, net	1,233,905	1,255,597	'	'
Investments in affiliates	1,465	1,715	'	'
Deferred tax assets	944	943	'	'
Other assets	69,501	70,095	'	'
Total assets	4,063,833	4,209,007	'	'
Current liabilities	'	'	'	'
Current borrowings	362,273	356,287	'	'
Accounts payable	73,533	71,967	'	'
Accrued expenses	80,040	74,868	'	'
Current portion of contingent consideration	2,959	4,131	'	'
Payroll and benefit-related liabilities	66,569	73,090	'	'
Accrued interest	9,991	8,725	'	'
Income taxes payable	21,817	23,821	'	'
Other current liabilities	35,308	22,231	'	'
Total current liabilities	652,490	635,120	'	'
Long-term borrowings	700,000	930,000	'	'
Deferred tax liabilities	517,433	514,715	'	'
Pension and postretirement benefit liabilities	102,194	109,498	'	'
Noncurrent liability for uncertain tax positions	56,687	55,152	'	'
Other liabilities	50,650	48,506	'	'
Total liabilities	2,079,454	2,292,991	'	'
Total common shareholders' equity	1,982,277	1,913,527	'	'
Noncontrolling interest	2,102	2,489	'	'
Total equity	1,984,379	1,916,016	1,801,527	1,781,537
Total liabilities and equity	4,063,833	4,209,007	'	'
Consolidation, Eliminations	'	'	'	'
Current assets	'	'	'	'
Accounts receivable, net	3,161	3,472	'	'
Accounts receivable from consolidated subsidiaries	-3,053,906	-2,880,648	'	'
Inventories, net	-25,977	-15,709	'	'
Deferred tax assets	-4	-3	'	'
Total current assets	-3,076,726	-2,892,888	'	'
Investments in affiliates	-7,012,091	-6,987,772	'	'
Deferred tax assets	-36,935	-39,410	'	'
Notes receivable and other amounts due from consolidated subsidiaries	-1,941,769	-1,936,618	'	'
Total assets	-12,067,521	-11,856,688	'	'
Current liabilities	'	'	'	'
Accounts payable to consolidated subsidiaries	-3,053,906	-2,880,648	'	'
Other current liabilities	-4	-4	'	'
Total current liabilities	-3,053,910	-2,880,652	'	'
Deferred tax liabilities	-36,934	-39,409	'	'
Notes payable and other amounts due from consolidated subsidiaries	-1,949,510	-1,940,100	'	'
Total liabilities	-5,040,354	-4,860,161	'	'
Total common shareholders' equity	-7,027,167	-6,996,527	'	'
Total equity	-7,027,167	-6,996,527	'	'
Total liabilities and equity	-12,067,521	-11,856,688	'	'
Parent Company	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	31,283	42,749	28,093	70,860
Accounts receivable, net	1,192	1,822	'	'
Accounts receivable from consolidated subsidiaries	40,046	42,865	'	'
Prepaid expenses and other current assets	13,916	15,200	'	'
Prepaid taxes	30,402	27,487	'	'
Deferred tax assets	20,136	20,218	'	'
Assets held for sale	2,901	1,669	'	'
Total current assets	139,876	152,010	'	'
Property, plant and equipment, net	3,939	14,189	'	'
Investments in affiliates	5,637,719	5,489,676	'	'
Deferred tax assets	33,425	35,877	'	'
Notes receivable and other amounts due from consolidated subsidiaries	963,322	1,049,344	'	'
Other assets	29,319	24,574	'	'
Total assets	6,807,600	6,765,670	'	'
Current liabilities	'	'	'	'
Current borrowings	357,573	351,587	'	'
Accounts payable	5,582	2,194	'	'
Accounts payable to consolidated subsidiaries	2,661,371	2,644,296	'	'
Accrued expenses	17,280	15,569	'	'
Payroll and benefit-related liabilities	16,472	15,976	'	'
Accrued interest	9,989	8,720	'	'
Other current liabilities	635	9,646	'	'
Total current liabilities	3,068,902	3,047,988	'	'
Long-term borrowings	700,000	930,000	'	'
Pension and postretirement benefit liabilities	50,913	57,406	'	'
Noncurrent liability for uncertain tax positions	12,649	11,389	'	'
Notes payable and other amounts due from consolidated subsidiaries	973,020	785,476	'	'
Other liabilities	19,839	19,884	'	'
Total liabilities	4,825,323	4,852,143	'	'
Total common shareholders' equity	1,982,277	1,913,527	'	'
Total equity	1,982,277	1,913,527	'	'
Total liabilities and equity	6,807,600	6,765,670	'	'
Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	3,235	14,500	'	1,989
Accounts receivable, net	10,588	10,948	'	'
Accounts receivable from consolidated subsidiaries	2,750,172	2,623,314	'	'
Inventories, net	208,536	211,165	'	'
Prepaid expenses and other current assets	5,175	6,870	'	'
Deferred tax assets	19,051	22,472	'	'
Assets held for sale	1,034	3,503	'	'
Total current assets	2,997,791	2,892,772	'	'
Property, plant and equipment, net	193,017	188,455	'	'
Goodwill	703,258	797,671	'	'
Intangible assets, net	722,652	962,243	'	'
Investments in affiliates	1,354,463	1,478,429	'	'
Notes receivable and other amounts due from consolidated subsidiaries	978,447	873,105	'	'
Other assets	7,628	7,447	'	'
Total assets	6,957,256	7,200,122	'	'
Current liabilities	'	'	'	'
Accounts payable	34,483	45,802	'	'
Accounts payable to consolidated subsidiaries	190,790	147,957	'	'
Accrued expenses	18,855	21,120	'	'
Current portion of contingent consideration	2,959	4,131	'	'
Payroll and benefit-related liabilities	14,501	21,818	'	'
Other current liabilities	29,153	7,517	'	'
Total current liabilities	290,741	248,345	'	'
Deferred tax liabilities	491,345	496,228	'	'
Pension and postretirement benefit liabilities	33,555	33,777	'	'
Noncurrent liability for uncertain tax positions	17,394	17,241	'	'
Notes payable and other amounts due from consolidated subsidiaries	872,248	957,451	'	'
Other liabilities	17,986	16,221	'	'
Total liabilities	1,723,269	1,769,263	'	'
Total common shareholders' equity	5,233,987	5,430,859	'	'
Total equity	5,233,987	5,430,859	'	'
Total liabilities and equity	6,957,256	7,200,122	'	'
Non-Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	202,864	374,735	253,325	264,190
Accounts receivable, net	286,779	279,048	'	'
Accounts receivable from consolidated subsidiaries	263,688	214,469	'	'
Inventories, net	173,908	138,165	'	'
Prepaid expenses and other current assets	19,295	17,740	'	'
Prepaid taxes	17,239	9,017	'	'
Deferred tax assets	11,314	10,230	'	'
Assets held for sale	5,226	5,256	'	'
Total current assets	980,313	1,048,660	'	'
Property, plant and equipment, net	146,452	123,256	'	'
Goodwill	670,098	556,532	'	'
Intangible assets, net	511,253	293,354	'	'
Investments in affiliates	21,374	21,382	'	'
Deferred tax assets	4,454	4,476	'	'
Notes receivable and other amounts due from consolidated subsidiaries	'	14,169	'	'
Other assets	32,554	38,074	'	'
Total assets	2,366,498	2,099,903	'	'
Current liabilities	'	'	'	'
Current borrowings	4,700	4,700	'	'
Accounts payable	33,468	23,971	'	'
Accounts payable to consolidated subsidiaries	201,745	88,395	'	'
Accrued expenses	43,905	38,179	'	'
Payroll and benefit-related liabilities	35,596	35,296	'	'
Accrued interest	2	5	'	'
Income taxes payable	21,817	23,821	'	'
Other current liabilities	5,524	5,072	'	'
Total current liabilities	346,757	219,439	'	'
Deferred tax liabilities	63,022	57,896	'	'
Pension and postretirement benefit liabilities	17,726	18,315	'	'
Noncurrent liability for uncertain tax positions	26,644	26,522	'	'
Notes payable and other amounts due from consolidated subsidiaries	104,242	197,173	'	'
Other liabilities	12,825	12,401	'	'
Total liabilities	571,216	531,746	'	'
Total common shareholders' equity	1,793,180	1,565,668	'	'
Noncontrolling interest	2,102	2,489	'	'
Total equity	1,795,282	1,568,157	'	'
Total liabilities and equity	$2,366,498	$2,099,903	'	'

Condensed_Consolidating_Statem1

Condensed Consolidating Statements of Cash Flows (Detail) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 29, 2014	Jun. 30, 2013
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	$120,161	$56,243
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-30,850	-36,897
Proceeds from sale of assets and investments	4,139	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-36,954
Investment in affiliates	-60	-50
Net cash used in investing activities from continuing operations	-55,306	-73,901
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	'
Repayment of long-term borrowings	-480,000	'
Debt issuance fees	-3,275	'
Proceeds from share based compensation plans and the related tax impacts	2,391	3,892
Payments to noncontrolling interest shareholders	-1,094	-736
Dividends	-28,093	-27,944
Net cash used in financing activities from continuing operations	-260,071	-34,275
Payments for contingent consideration	'	-9,487
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,531	-1,437
Net cash used in discontinued operations	-1,531	-1,437
Effect of exchange rate changes on cash and cash equivalents	2,145	-2,251
Net decrease in cash and cash equivalents	-194,602	-55,621
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	237,382	281,418
Consolidation, Eliminations	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	-74,045	-51,327
Cash Flows from Investing Activities of Continuing Operations:	'	'
Intercompany dividends received	-229,782	'
Net cash used in investing activities from continuing operations	-229,782	'
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany dividends paid	303,827	51,327
Net cash used in financing activities from continuing operations	303,827	51,327
Parent Company	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	-49,306	-58,665
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-2,019	-711
Proceeds from sale of assets and investments	1,669	'
Investment in affiliates	-60	-50
Net cash used in investing activities from continuing operations	-410	-761
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	'
Repayment of long-term borrowings	-480,000	'
Debt issuance fees	-3,275	'
Proceeds from share based compensation plans and the related tax impacts	2,391	3,892
Dividends	-28,093	-27,944
Intercompany transactions	298,758	41,548
Net cash used in financing activities from continuing operations	39,781	17,496
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,531	-837
Net cash used in discontinued operations	-1,531	-837
Net decrease in cash and cash equivalents	-11,466	-42,767
Cash and cash equivalents at the beginning of the period	42,749	70,860
Cash and cash equivalents at the end of the period	31,283	28,093
Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	277,376	92,513
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-14,080	-28,617
Proceeds from sale of assets and investments	2,470	'
Payments for businesses and intangibles acquired, net of cash acquired	'	1,500
Net cash used in investing activities from continuing operations	-11,610	-27,117
Cash Flows from Financing Activities of Continuing Operations:	'	'
Intercompany transactions	-277,031	-42,063
Intercompany dividends paid	'	-17,400
Net cash used in financing activities from continuing operations	-277,031	-67,385
Payments for contingent consideration	'	-7,922
Cash Flows from Discontinued Operations:	'	'
Net decrease in cash and cash equivalents	-11,265	-1,989
Cash and cash equivalents at the beginning of the period	14,500	1,989
Cash and cash equivalents at the end of the period	3,235	'
Non-Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements Captions [Line Items]	'	'
Net cash (used in) provided by operating activities from continuing operations	-33,864	73,722
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-14,751	-7,569
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-38,454
Intercompany dividends received	229,782	'
Net cash used in investing activities from continuing operations	186,496	-46,023
Cash Flows from Financing Activities of Continuing Operations:	'	'
Payments to noncontrolling interest shareholders	-1,094	-736
Intercompany transactions	-21,727	515
Intercompany dividends paid	-303,827	-33,927
Net cash used in financing activities from continuing operations	-326,648	-35,713
Payments for contingent consideration	'	-1,565
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	'	-600
Net cash used in discontinued operations	'	-600
Effect of exchange rate changes on cash and cash equivalents	2,145	-2,251
Net decrease in cash and cash equivalents	-171,871	-10,865
Cash and cash equivalents at the beginning of the period	374,735	264,190
Cash and cash equivalents at the end of the period	$202,864	$253,325